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The quinolones are a class of antibiotics that target DNA gyrase and
topoisomerase IV, enzymes involved in DNA replication. DNA gyrase has two A
subunits encoded by gyrA, and two B subunits encoded by gyrB. Topoisomerase IV
is also tetrameric, and is encoded by grlA and gr/B in Staphylococcus aureus.
Previous research has suggested that DNA gyrase is the primary quinolone target in
Gram-negative organisms while topoisomerase IV is the primary target in
Gram-positive organisms. In S. aureus, resistance to the quinolones arises through
mutations within the quinolone resistance determining regions (QRDRs) of the gyrA
or grlA genes. However, low-level resistance has also been attributed to mutations in
gyrB or gr/B, and with enhanced expression of cell surface efflux proteins.
Historically, the quinolones have had good activity against Gram-negative organisms
but have been less effective against Gram-positive organisms. Moxifloxacin is a new
8-methoxyquinolone that has good activity against Gram-positive organisms. In this
thesis the activity of moxifloxacin against sensitive laboratory strains and clinical
isolates of S. aureus was investigated by time-kill kinetics. The bactericidal activity
of moxifloxacin under different growth conditions was established in order to
determine the mechanisms of killing action. Subsequently, the killing kinetics
against laboratory derived mutants with characterised mutations within the QRDRs
of gyrA and grlA were also investigated. Mutations within gyrA and gr/A did not
alter the pattern of killing by moxifloxacin.
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To investigate the sequential development of resistance a series of low-, medium-
and high-level resistant mutants were selected in a step-wise manner with
moxifloxacin. The QRDRs of gyrA and grlA were characterised by DNA
sequencing. Although all five first-step mutants had elevated MICs to moxifloxacin,
only one was found to have a Ser80 to Phe mutation in grlA. No other mutations
were detected in any other first-step mutants. All second-step mutants were found to
have a gyrA mutation, and two strains also had an inherited grlA mutation. However,
the strains with two mutations did not have higher MICs of moxifloxacin than other
second-step mutants. High level resistance in third-step mutants was conferred by a
grlA mutation in addition to the inherited gyrA mutation. Subsequent mutant
selections with ciprofloxacin gave similar results with a single first step strain
showing a grlA mutation, while several second-step mutants had only gyrA
mutations. These results indicate DNA gyrase and not topoisomerase IV as the
primary target of moxifloxacin in S. aureus. No mutations could be detected in the
region ofgyrB associated with quinolone resistance in first-step mutants. Uptake and
accumulation assays did not show enhanced efflux of moxifloxacin, indicating that
low-level moxifloxacin resistance in these strains is facilitated by an unknown
mechanism of resistance.
The activity and selection of resistance in vivo was investigated in a murine
subcutaneous abscess model. Moxifloxacin was found to kill S. aureus in
subcutaneous abscesses in a dose-dependent manner. In vivo mutants were selected
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from subcutaneous abscesses and characterised by PCR amplification and DNA
sequencing. One first step mutant had a grlA mutation but no other mutations were
apparent within the QRDRs in first step mutants; the second step mutant had a gyrA
mutation but no gr/A mutation. The findings of this thesis are in contrast to those of
previous researchers and indicate that the development of resistance and
identification of the primary target of quinolones in S. aureus may be strain, drug or
method dependent and not as simple as previous research has suggested. The
relationship between these data and the development of high-level quinolone
resistance in clinically significant S. aureus strains remains unclear.
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FDA Food and Drug Administration, USA
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The discovery of antibiotic compounds in the early part of this century led to a
revolution in the treatment of infectious diseases. So successful were antibiotics, that
in 1969 the Surgeon General of the United States of America addressed Congress
regarding the efficacy of antibiotics with the following statement "The time has come
to close the book on infectious disease". Unfortunately this statement was
premature, as bacteria have continued to show themselves to be adept at overcoming
antimicrobial challenges with which they are faced. In fact today up to 40% of
Staphylococcus aureus strains in USA and 80% in China are resistant to not just one,
but multiple antibiotics (Williams, 1999).
/. 2 Quinolone Antibiotics
The creation of new antibacterial agents is fraught with difficulties, and the majority
of agents in use are still natural microbial products rather than synthetic chemicals.
One of the first synthetic antibiotics, nalidixic acid, was discovered as a by-product
of the purification process of the anti-malarial drug chloroquine (Lesher et al. 1962).
Nalidixic acid was the first in a new class of antibacterial agents known as the
quinolones. It showed good activity against certain Gram-negative organisms,
notably the Enterobacteriaceae (Lesher et al. 1962), but had only poor activity
against S. aureus and other Gram-positive bacteria. This limited spectrum of activity
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combined with poor serum and tissue concentrations, when given in vivo, restricted
the clinical applications of nalidixic acid to the treatment of urinary tract infections.
It took almost 20 years of research and development into derivatives and structural
analogues before the breakthrough of incorporating a fluorine atom at position C-6 of
the quinolone core structure led to the construction of fluoroquinolones, providing a
new spectrum of clinically useful drugs with superior activity to nalidixic acid.
Figure 1.1 shows the structure of nalidixic acid and the fundamental fluoroquinolone
structure.
Figure 1.1: Nalidixic acid and fluoroquinolone core
a) Nalidixic acid b) Fluoroquinolone core
1.3 Structure-Activity Relationships
Today more than 10 000 analogues of nalidixic acid and the fluoroquinolones have
been described, although very few have been licensed for clinical use. However, this
abundance of compounds has facilitated study of the structure-activity relationships
between quinolones and their applications both in vitro and in vivo. Such studies
2
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have revealed some correlation between substituents at key positions within the
quinolone core structure and the bactericidal spectrum, in vivo toxicity and, most
recently, resistance potential of these agents (Zhao et al. 1998; Tillotson, 1996).
1.3.1 Position 1
The fundamental quinolone core structure is shown in Figure 1.1b, with all possible
sites of modification labelled numerically. The substituent at position 1 controls the
overall antimicrobial potency of the agent and is optimally a cyclopropyl group as
found in ciprofloxacin (Figure 1.2a) and sparfloxacin (Figure 1.2b) giving significant
activity against Gram-negative bacteria such as Enterobacteriaceae and
Pseudomonas aeruginosa (Tillotson, 1996). The sterical, spacial and electron
donation effects of larger moieties at this position can have an adverse influence on
the biological activity (Chu and Fernandes, 1989), although substitution of a 2,4-
difluorophenyl group may enhance activity against anaerobic bacteria (Domagala,
1994).
Figure 1.2: Ciprofloxacin and sparfloxacin
COOH




1.3.2 Positions 2 - 6
Few changes at positions 2, 3 and 4 have been investigated primarily because
addition of large substituents causes steric hindrance preventing the interactions of
the carboxyl group at position 3 and the oxygen molecule at position 4 with the
bacterial DNA/DNA gyrase complex. Such a hindrance substantially decreases the
antibacterial activity of the compound (Domagala, 1994).
Figure 1.3: Sparfloxacin and grepafloxacin
CH,
a) Sparfloxacin b) Grepafloxacin
Alterations at position 5 have not been extensively studied. However, newer agents
such as sparfloxacin (Figure 1.3a) and grepafloxacin (Figure 1.3b) with additional
moieties at this position have enhanced activity against Gram-positive organisms
compared to earlier agents. The addition of small highly active atoms, particularly
fluorine, at position 6 generate a significant increase in activity possibly by
enhancing cell penetration and binding to the bacterial DNA/DNA gyrase complex




Alterations at position 7 have been extensively studied and a range of different
substituent groups alter the spectrum of activity. Molecules with large cyclic groups,
particularly those incorporating a nitrogen atom, have increased antibacterial activity
and better pharmacokinetic profiles (Tillotson, 1996).
Figure 1.4: Tosufloxacin and clinafloxacin
COOH COOH
a) Tosufloxacin b) Clinafloxacin
The aminopyrrolidine group of tosufloxacin (Figure 1.4a) and clinafloxacin (Figure
1.4b) enhances anti-Gram-positive activity. Ciprofloxacin (Figure 1.5a) has a
piperazine group at this position, enhancing anti-Gram-negative activity. Similarly,
sparfloxacin (Figure 1.5b) has a piperazine group enhancing anti-Gram-negative




Figure 1.5: Ciprofloxacin and sparfloxacin
r> Mt-i rt
CH3
a) Ciprofloxacin b) Sparfloxacin
1.3.4 Position 8
Substitution of carbon at position 8 with C-8-chloro (Figure 1.6a) or C-8-fluoro may
produce derivatives with greater activity in vivo due to enhanced absorption, but
which are often less active in vitro (Chu and Fernandes, 1989).
Figure 1.6: CHnafloxacin and ofloxacin
COOH COOH
a) Clinafloxacin b) Ofloxacin
Ofloxacin (Figure 1.6b) has oxygen at position 8 that has been connected with good




Predicting the activity of structural analogues and derivatives of quinolones is
difficult because of the risk of producing compounds with high in vivo toxicity. For
example, changes that enhance one aspect of quinolone activity, such as in vitro
activity, may have a detrimental effect on the pharmacokinetic profile (Domagala,
1994). Quinolones can cause a number of toxic effects in vivo including
gastrointestinal symptoms, skin rash, phototoxicity, arthropathy, crystalluria and
CNS effects (Domagala, 1994). Some in vivo toxicity can be associated with
position-specific structural features of quinolone molecules. For example,
phototoxicity has been linked to substitution of halogens at position 8 (Man et al.
1999; Tillotson, 1996). Phototoxicity is an oxygen-dependent non-immunogenic
reaction caused by the decay of the quinolone molecule after exposure to UVA
radiation. Products of this decay process include singlet oxygen and radicals which
can cause severe damage to tissues (Domagala, 1994). This form of toxicity has
been serious enough to warrant discontinuation of development ofmany compounds
such as BAY 3118 that otherwise showed great potential based on in vitro activity
(Tillotson, 1996).
Although side effects may be rare, they can be sufficiently serious as to severely
compromise the therapeutic value of the drug. Trovafloxacin, for example, is one of
the newer quinolones with good activity against Gram-positive bacteria such as
S. aureus and respiratory pathogens. It was licensed in the USA in December 1987,
where it has been on the market since February 1998. In clinical trials of
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approximately 7000 patients prior to licensing there were no reports of serious
adverse hepatic reactions. However, in July the FDA issued a public health advisory
indicating that at least 14 cases of acute liver failure, six of which were fatal, had
been reported which were strongly associated with use of trovafloxacin (Nightingale,
1999). Although the drug has not been withdrawn, the FDA recommends that
patients for whom this drug is being considered should meet stringent criteria to
ensure that the benefit for the patient sufficiently outweighs the potential risk.
Therefore it seems unlikely that this drug will be routinely prescribed in the future.
Similarly, in a press release in October, Glaxo Wellcome voluntarily withdrew
grepafloxacin after concerns over "a small number of severe cardiovascular events"
which suggested that the risk to patients outweighed the benefits of therapy (Glaxo
Wellcome, 1999).
1.5 Moxifloxacin
A notable improvement in recent years has been the development of quinolones that
have enhanced activity against Gram-positive organisms, an area of efficacy in
which the majority of earlier compounds were lacking. BAY 12-8039, known as
moxifloxacin (Figure 1.7), is a new generation fluoroquinolone that has enhanced
activity against Gram-positive organisms compared to older agents such as
ciprofloxacin (Alcala el al. 1999; Balfour and Wiseman, 1999; Dalhoff et al. 1996).
Moxifloxacin has a cyclopropyl group at position 1, which in ciprofloxacin and
sparfloxacin is associate with activity against Enterobacteriaceae and Pseudomonas
aeruginosa. It also has oxygen at position 8, which in ofloxacin has been connected
8
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with good in vivo efficacy. Moxifloxacin has a large R7 group, which in sparfloxacin
and ciprofloxacin has been linked to better biological activity. Within this group,
nitrogen is required for oral efficacy, and ring alkylation enhances Gram-positive





Early activity and pharmacokinetic studies of moxifloxacin confirm some of these
theoretical predictions of activity based on structure-activity studies of earlier
quinolones. Moxifloxacin has a broad spectrum of activity against both Gram-
negative and Gram-positive organisms, although activity against Pseudomonas
aeruginosa is lower than might be predicted based on the molecular structure
(Dalhoff et al. 1996). At a single dose of 400mg per day it penetrates well into
tissues and rarely causes adverse CNS or phototoxic effects, although gastrointestinal





Although quinolones have been available clinically for almost two decades their
mechanisms of bactericidal activity are still not fully understood. Some features are
easily observed microscopically. For example, they cause a number of phenotypic
changes including cell filamentation and loss of septation by preventing the
completion of cell division (Maxwell and Critchlow, 1998). Other aspects requiring
analysis by molecular techniques are discussed in section 1.7.4.
1.6.1 Dose-Response and Optimum Bactericidal Concentration
In the early 1980s Smith demonstrated the 'classic' bactericidal activity pattern of the
quinolones - the biphasic dose-response curve shown in Figure 1.8. Fie
demonstrated that although the number of surviving cells decreased as the
concentration with which challenge was made increased, there was a minimum
survival point (indicated on figure 1.8) at a fixed concentration after which the
number of surviving cells appeared to increase again. This minimum concentration
was termed the most bactericidal concentration, later called the optimum bactericidal
concentration (OBC) (Lewin and Smith, 1990). It has been demonstrated for a
number of quinolones including nalidixic acid, norfloxacin and ciprofloxacin and
others (Lewin et al. 1989; Lewin and Smith, 1988; Ratcliffe and Smith, 1985;
Ratcliffe and Smith, 1984; Smith, 1984; Crumplin and Smith, 1975).
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Figure 1.8: Biphasic Dose Response Curve
Concentration of Quinolone
Smith suggested that the increased survival of cells challenged with concentrations
greater than the OBC resulted from the excessively high concentrations of quinolone
inhibiting bacterial RNA synthesis, a process thought to be crucial to the bactericidal
action of quinolones (Crumplin and Smith, 1975). Interestingly the OBC does not
directly relate to the minimum inhibitory concentration (MIC) at which concentration
quinolones are merely bacteriostatic (Smith and Zeiler, 1998).
1.6.2 Mechanisms of Action
While investigating the effects of protein and RNA synthesis inhibitors, Smith was
able to demonstrate the possibility of various mechanisms of action of quinolones.
The simultaneous challenge of a broth culture with both bactericidal concentrations
of quinolone and a bacteriostatic concentration of an inhibitor such as rifampicin (or
chloramphenicol in the case of Gram-positives) investigated the possibility of
11
Chapter 1: Introduction
quinolone activity in the absence of RNA synthesis. Similarly, incubation of a
culture challenged with quinolone in a minimal medium, such as phosphate buffered
saline (PBS), with a concomitant lack of available energy resources, investigated the
activity of drug when cells were not actively growing. Based on such experiments,
Smith (1984) developed the hypothesis of three mechanisms of bactericidal activity
possibly exhibited by quinolones. Mechanism A, demonstrated by all quinolones, is
exhibited against actively growing cells and can be lost by addition of inhibitors or
by prevention of active cell division. It is the only mechanism of older quinolones
such as nalidixic acid (Lewin et al. 1991b). Mechanism B, however, can be
demonstrated irrespective of active cell division and does not require active RNA
synthesis (Smith, 1984). Mechanism B has been found in addition to mechanism A
for a number of fluorinated quinolones including ciprofloxacin, ofloxacin (Ratcliffe
and Smith, 1984), lomefloxacin (Lewin et al. 1989) and sparfloxacin (Lewin et al.
1992). An additional mechanism B1 described for clinafloxacin (Lewin and Amyes,
1990) requires active cell division but is independent of active protein or RNA
synthesis. Finally, mechanism C does require protein and RNA synthesis but not
actively growing cells. This mechanism has only been detected with norfloxacin and
enoxacin in E. coli (Lewin et al. 1989; Ratcliffe and Smith, 1985). The four
mechanisms are summarised in Table 1.1. Not all quinolones are found to have the
same bactericidal mechanisms against all species. The relationship between
mechanisms of action and activity is somewhat complex; mechanisms of action seem
to be quinolone, organism and concentration specific. For example, both
ciprofloxacin and ofloxacin kill E. coli by mechanisms A and B. FTowever,
12
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ciprofloxacin is a much more active compound against this species. Conversely,
both drugs have similar activity against S. aureus, although ofloxacin kills by both
mechanisms A and B while ciprofloxacin apparently only exhibits mechanism A
(Lewin and Smith, 1988). Mechanism B seems to be of key importance to the
activity of these two quinolones. For example they have poor activity against E.
faecalis and S. pneumoniae against which they demonstrate no or only weak killing
by mechanism B (Morrissey and Smith, 1993; Lewin et al. 1991a).
Table 1.1: Requirements for mechanisms of quinolone action





It is still unclear exactly how these killing mechanisms, and the concentrations at
which they begin to be manifested, relate to intracellular quinolone targets and
binding. However, some evidence seems to correlate the concentration of
norfloxacin required to inhibit DNA supercoiling (Shen et al. 1989a) with the
concentration at which mechanism C is initiated (Smith and Zeiler, 1998). Very little
work has so far been done to investigate any effects of specific quinolone resistance




Within a living bacterial cell DNA exists in a dynamic equilibrium of positive and
negative superhelical twists controlled by topoisomerases. Bacterial topoisomerases
alter the topology of DNA by breaking and passing DNA strands. This, in turn,
brings about changes to the tertiary DNA structure by introducing or removing
superhelical twists (Cozzarelli, 1980). This has implications for DNA replication, a
process dependent on the degree of DNA supercoiling. There are two classes of
topoisomerase: Type I, which includes topoisomerase I and topoisomerase III, can
break single strands of a double stranded DNA complex, then pass a single strand
through the break and reseal the incised portion. This process relaxes the negative
superhelical twists in DNA (i.e. introduces positive supercoils). In contrast, type II
topoisomerases such as DNA gyrase and topoisomerase IV break both strands of
double stranded DNA, and then pass double stranded DNA through before resealing
the break (Maxwell and Critchlow, 1998). Activity inhibition studies ofDNA gyrase
and topoisomerase IV, where binding of the drug reduces enzyme activity, have
shown that both these enzymes are targets of the quinolones (Ferrero et al. 1994;
Gellert et al. 1977). Evidence that quinolone resistance mutations, described later in
section 1.9, map to the genes encoding DNA gyrase and topoisomerase IV also




DNA gyrase (known as topoisomerase II in mammalian cells) is the only
topoisomerase able to introduce negative supercoils into DNA (Gellert et al. 1977;
Gellert et al. 1976). This means that it is able to twist DNA so that it is underwound
relative to linear DNA. The action of DNA gyrase is counterbalanced by
topoisomerase I, which is able to remove these twists thereby maintaining and
adjusting the superhelical density of DNA (Hooper, 1998). By adding negative
supercoils ahead of the replication fork, and at sites of transcription by RNA
polymerase, DNA gyrase is able to maintain the integrity of DNA replication and
transcription by preventing inhibitory levels of supercoiling from accumulating
(Hooper, 1998).
1.7.2 Topoisomerase IV
Topoisomerase IV, which shows considerable homology to DNA gyrase, can also
remove negative and positive superhelical twists. It is a more efficient decatanase
than DNA gyrase (Hoshino et al. 1994), and is particularly efficient at removing
circles of interlocked or catenated DNA. It is the principal enzyme involved in
releasing newly replicated DNA from the interlocked position with the parent DNA,
enabling daughter chromosomes to segregate into daughter cells (Khodursky et al.
1995; Adams et al. 1992). To some extent DNA gyrase and topoisomerase are able
to compensate for each other if an activity deficiency is present in one enzyme (Kato
etal. 1992; Kato et al. 1990).
15
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Both DNA gyrase and topoisomerase IV are tetrameric enzymes composed of two A
and two B subunits (Drlica and Zhao, 1997). The gyrA and gyrB genes encode these
subunits respectively for DNA gyrase. In S. aureus, grlA and gr/B encode the
subunits of topoisomerase IV, and are equivalent to parC and parE in Escherichia
coli.
1.7.3 Interactions of DNA Gyrase and Topoisomerase IV with DNA
Taking DNA gyrase as an example, the interaction between the enzyme and DNA at
a molecular level can be described as follows. The A subunit interacts directly with
DNA via the tyrosine residue at position 122 which constitutes the active site and is
located within the highly conserved N-terminal region of the protein (Maxwell and
Critchlow, 1998). Hydrolysis of ATP to ADP by the B subunit provides sufficient
energy to drive the supercoiling activity of the enzyme (Drlica and Zhao, 1997). It
also facilitates enzyme turnover, restoring the tertiary enzyme conformation to a
ready state for subsequent catalytic activity. Clearly therefore the ratio of ATP to
ADP can exert some degree of control on the level of DNA supercoiling. Since this
ratio is influenced by external environmental factors such as salt concentration
(Hsieh et al. 1991), external factors can directly influence genomic activity.
Homeostatic regulation has also been described in which a decrease in supercoiling,
possibly caused by the presence of inhibitors, upregulates expression of DNA gyrase
thereby increasing supercoiling levels again (Menzel and Gellert, 1983).
The interaction of DNA gyrase and DNA appears to form a transiently stable
cleavage complex (Reece and Maxwell, 1989), although the exact details of how this
16
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occurs have yet to be clarified. Figure 1.9 shows a schematic diagram of the DNA
gyrase/DNA interaction (Drlica and Zhao, 1997).






Adapted from Drlica and Zhao (1997)
The A subunit of DNA gyrase binds to DNA (Figure 1.9a), resulting in a region of
approximately 130 base pairs of DNA wrapping around the DNA gyrase molecule
(Maxwell and Critchlow, 1998). The B subunit then binds ATP causing a change in
the tertiary conformation of the DNA gyrase molecule (Figure 1.9b). This structural
adjustment breaks the double strands of DNA in a four base stagger, effectively
pulling the double stranded DNA apart to form a gate (Morrison and Cozzarelli,
1979). A temporary covalent bond is formed between the 5' phosphate of DNA and
the Tyrl22 active site of GyrA (Horowitz and Wang, 1987). A double strand of
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DNA is then passed through this open gate (Figure 1.9b and c), and the DNA break
is closed (Figure 1.9d). Flydrolysis of ATP to ADP by GyrB completes turnover of
the enzyme restoring it to the relaxed conformation and freeing it ready to bind again
as required.
1.7.4 Interactions ofQuinolones with DNA Gyrase and Topoisomerase IV
Quinolones are thought to bind to the cleavable DNA-gyrase complex and prevent
the resealing of double stranded breaks in DNA. This in turn initiates the SOS
response (Hooper, 1998), inducing expression of several genes responsible for repair
of damaged DNA or lesions in DNA replication (Walker, 1984). Quinolone
inhibition of the cleavable complex thus inhibits DNA replication and transcription.
Critchlow and Maxwell (1996) showed that the normally transient GyrA-GyrB-DNA
complex is stabilised by the addition of a quinolone, but exactly how this occurs is
still unclear. The interaction process with topoisomerase IV is thought to be similar
as quinolone binding inhibits DNA decatenation and relaxation in a similar manner
(Ng et al. 1996; Chen et al. 1996; Khodursky et al. 1995; Ferrero et al. 1994;
Hoshino et al. 1994; Kato et al. 1992). Many methods of study have been used to
examine the binding of quinolones to cleavable complexes. However, the results
have varied depending on the methodology employed (Orphanides and Maxwell,
1994; Rau et al. 1987; Fisher et al. 1981; Morrison and Cozzarelli, 1981) and a
clear consensus on the exact mechanism has yet to be reached. At the present time it
seems that the only conclusion to be drawn is that quinolones trap the cleavable
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complexes of the enzyme by binding and blocking after or immediately before the
double stranded DNA break is incurred.
1.8 Drug-DNA-enzyme binding models
Although it is not clear at what point the quinolone interacts with the DNA gyrase-
DNA complex, certain features of binding have been determined. Work by Willmott
and Maxwell (1993) indicated that 'H-labelled norfloxacin does not bind to DNA
gyrase or DNA alone, although significant binding to a complex of both DNA gyrase
and DNA can be detected (Yoshida et at. 1993). Conversely, Shen et al (1989a)
were able to detect quinolone binding to relaxed DNA alone, although binding was
increased if gyrase was present. In the light of these apparently contradictory results
several drug-binding models have been suggested.
1.8.1 The Cooperative Drug Binding Model
The first of these is the cooperative drug-binding model of Shen et al (1989b) shown
in Figure 1.10. DNA gyrase, with A and B subunits, is indicated by dotted outlines.
Four stacked quinolone molecules are shown as filled and hatched boxes in the
center of the figure. In this hypothesis, DNA gyrase binds to DNA and cleaves it in
an ATP-dependent process leaving a four base stagger of single-stranded DNA at the
DNA gyrase active site.
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Figure taken from Shen et al (1989b)




b) Four stacked moxifloxacin moleculesa) Single moxifloxacin molecule
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Four quinolone molecules stack as shown in Figure 1.11, and bind to the exposed
DNA strands via hydrogen bonds between single stranded DNA donors and the
carbonyl and carboxyl groups at positions 3 and 4 on the quinolone nucleus. One
problem with this model is that it requires cleavage of DNA; however quinolones
have been shown to bind to complexes formed with DNA gyrase mutants that do not
have a Tyrl22 active site implying that DNA cleavage is not actually necessary for
quinolone binding (Critchlow and Maxwell, 1996).
1.8.2 The Magnesium Bridge Model
A second model known as the magnesium bridge model has been suggested (Figure
1.12). Binding of quinolones to single stranded non-linear DNA is known to be
Mg2f dependent (Palu et al. 1992; Palu et al. 1988).





Figure taken from Palumbo et al (1993)
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In this model is it proposed that Mg2+ forms a bridge between the phosphate of the
nucleic acid and the carbonyl and carboxyl groups of the quinolone, while the C-7
2_j_and N-l quinolone substituents interact with DNA gyrase. Clearly the Mg
concentration is crucial to this process as insufficient magnesium would prevent
bridge formation, while an excess would saturate both the DNA and the quinolone.
As with the previous hypothesis, this model requires binding of quinolone to single
stranded DNA produced by the cleavage process, however the presence of cleaved
duplex DNA has been shown to be irrelevant to quinolone binding (Critchlow and
Maxwell, 1996).
Both the models described above assume that the C-7 substituent of a quinolone
interacts with gyrase, but this seems highly unlikely given the vast diversity of such
substituents (see section 1.3).
1.8.3 Other Binding Models
Several other models with less supporting evidence have been proposed. The pocket
binding model suggested by Yoshida et al (1993) supposes that quinolones bind in a
pocket of the gyrase-DNA complex that appears during the DNA cleavage and
reunion process, and that quinolone binding affinity is determined by both the GyrA
and GyrB subunits of the enzyme. Mutations could therefore alter the shape of the
pocket preventing efficient binding. Another model, presented by Fan et al (1995),
is based on the intercalation of quinobenzoxazines. These drugs are structural
analogues of norfloxacin, which inhibit mammalian topoisomerase II although they
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have no antibacterial activity. This model also presupposes a dependence on Mg2+ as
a bridge between the drug and DNA molecules as suggested in other models.
However, it is based on intercalation of the drug into the DNA double helix structure,
something which has been discounted by other studies (Shen and Pernet, 1985).
Many questions remain to be answered before a more accurate model can be
presented. At the present time it is not clear which amino acids in DNA gyrase and
topoisomerase IV are actually involved in quinolone binding. The constituents of the
quinolone molecule, that interact with DNA gyrase or topoisomerase IV, and the
manner in which they do so must also be determined. If these basic aspects of
quinolone action can be clarified, a more accurate hypothesis of how quinolones,
DNA and topoisomerases interact may be formulated. At the present time it may
only be concluded that quinolones bind to cleavable complexes by a process in which
Mg2+ plays a key role.
1.9 Mechanisms ofQuinolone Resistance
Bacteria have an intrinsic potential for genetic change and hence mutations, which
allow them to overcome antibiotic challenge, frequently arise. Three mechanisms of
quinolone resistance have been described so far in S. aureus: mutations in gyrA and
gyrB, the genes encoding the A and B subunits of DNA gyrase; mutations in gr/A
and grlB, the equivalent genes that encode topoisomerase IV; altered expression of
transmembrane efflux proteins. Resistance to the quinolones is chromosomal rather
than plasmid encoded and, in the early years of quinolone development, this gave
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rise to speculation that quinolone resistance would not develop as a serious clinical
problem. Although few clinically significant pathogens such as methicillin-sensitive
S. aureus (MSSA), E. coli, and Klebsiella species in the UK currently show any
quinolone resistance (Schmitz et al. 1999), the number of reported quinolone
resistant strains isolated globally is slowly increasing (Thomson, 1999). In addition,
a recent report (Martinez-Martinez et al. 1998) has shown that it is possible to
transfer quinolone resistance by plasmid vector, giving the potential for rapid spread
of resistance in the future.
1.9.1 Mutations in DNA Gyrase
A number of point mutations occur within the gyrA and gyrB genes of DNA gyrase
that reduce sensitivity to quinolones. Since there is a high degree of homology
between different bacterial species, these mutations map to equivalent positions on
most bacterial genomes. In gyrA a number ofmutational hotspots, so called because
they have a greater propensity for mutation that other codons, have been identified
within a region of approximately 300 base pairs. This gene segment has been termed
the quinolone resistance determining region (QRDR) (Yoshida et al. 1990a). The
most common sites of mutation in the QRDR of S. aureus are at codons 84, 85 and
88 (equivalent to 83, 84 and 97 in E. coli), and numerous point mutations have been
described in both laboratory strains and clinical isolates (Schmitz et al. 1998;
Takahashi et al. 1998; Fitzgibbon et al. 1998; Wang et al. 1998; Deplano et al.
1997; Ferrero et al. 1995; Ito et al. 1994; Nakanishi et al. 1991; Sreedharan et al.
1990). Similar mutations at equivalent positions have been seen, if looked for, in
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most other species including E. coli (Yonezawa et al. 1995; Vila et al. 1994;
Yoshida et al. 1990a) and Streptococcus pneumoniae (Varon et al. 1999; Pan and
Fisher, 1997; Tankovic et al. 1996).
GyrB mutations have generally only been described in clinical strains and seem to
have a modest effect on sensitivity to quinolones compared to gyrA mutations
(MunozBellido et al. 1999; Schmitz et al. 1998; Takahashi et al. 1998; Ito et al.
1994). Such mutations have been described less frequently than mutations in gyrA
and thus there is no apparent equivalent to the QRDR of gyrA within this gene.
However, it is difficult to draw conclusions as to their precise role since most strains
in which they have been found also have multiple mutations in gyrA and
topoisomerase IV which mask the effect ofmutations in gyrB.
1.9.2 Mutations in Topoisomerase IV
As topoisomerase IV has a high degree of homology to DNA gyrase, it is not
surprising that a region analogous to the QRDR of DNA gyrase has also been
described in the GrlA subunit of topoisomerase IV (Ferrero et al. 1994). In fact in
many organisms, including S. aureus, the mutation hotspots within grlA (parC in E.
coli) map to codons equivalent to those within the QRDR of gyrA (ElAmin et al.
1999; Deguchi et al. 1997; Vila et al. 1997; Yamagishi et al. 1996; Ng et al. 1996;
Heisig, 1996; Pan and Fisher, 1996; Ferrero et al. 1995; Ferrero et al. 1994;
Yamagishi et al. 1996; Yamagishi et al. 1996; Yamagishi et al. 1996; Yamagishi et
al. 1996). The most common grlA mutations are in codons 80 and 84 (equivalent to
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codons 84 and 88 in gyrA). Mutations within S. aureus grlB have rarely been
described and confer only a small reduction in sensitivity to quinolones (Schmitz et
al. 1998; Tanaka et al. 1998). Therefore it appears that, as with gyrB, mutations
within this gene may be of lesser importance to clinical quinolone resistance.
1.9.3 Resistance by Enhanced Efflux
Several multi-drug efflux pumps have been described in a number of bacterial
species. The NorA pump described in S. aureus (Trucksis et al. 1991; Yoshida et al.
1990b; Ubukata et al. 1989) is a chromosomally encoded active efflux pump
requiring proton motive force, and is not a passive protein channel (Kaatz et al.
1993). It is inherently expressed in wild-type cells but exhibits only a very low level
of quinolone efflux, showing a preference for hydrophilic quinolones such as
norfloxacin (Piddock et al. 1999b; Kaatz et al. 1993; Mortimer and Piddock, 1991).
Such efflux pumps are transmembrane proteins that have broad substrate specificity
i.e. they are able to export a variety of different molecules from the bacterial cell, and
are not restricted to efflux of quinolones alone. Although the natural role of NorA
has yet to be determined, it shows a high degree of sequence similarity to the Bmr
protein from Bacillus subtilis (Yoshida et al. 1990b). In addition to quinolones, Bmr
is known to mediate the efflux of a number of toxins such as ethidium bromide from
the cell (Neyfakh, 1992). NorA is also able to efflux a number of structurally diverse
compounds (Kaatz and Seo, 1995). In fact, since quinolones are synthetic and not
naturally occurring compounds their export by efflux pumps is a fortuitous
coincidence for the bacterium. The natural low-level expression of an efflux pump
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may have little significant effect on the sensitivity of an organism, unless the
wild-type gene is overexpressed thereby having a greater effect in reducing
sensitivity to quinolones (Kaatz et al. 1993). Overexpression may be induced by
pre-exposing the bacterium to a suitable substrate (Kaatz and Seo, 1995), and may be
due to a single nucleotide change in the norA promoter (Ng et al. 1994).
Overexpression increases the number of efflux proteins present on the cell surface
above wild-type levels of expression, allowing the bacterium to export the antibiotic
more rapidly. This may sufficiently reduce the intracellular quinolone concentration
so that fatal toxic effects are prevented and survival time increases. Extending the
survival period after antibiotic challenge may allow the cell to develop resistance
mutations within gyrase or topoisomerase IV that will enable it to survive subsequent
challenges. Resistance by enhanced efflux can be detected by observation of
intracellular quinolone accumulation. The introduction of inhibitors such as the plant
alkaloid reserpine, or protonophores such as CCCP into a broth culture can
significantly increase the intracellular quinolone concentration if NorA is being
overexpressed (Brenwald et al. 1997).
As a resistance mechanism, efflux can only overcome exposure to low levels of
quinolone, and it is not clear at what point efflux mutations occur in the overall
development of resistance. Some authors have indicated that they may occur early in
the progression to high level resistance in vivo as an alternative to the development
of topoisomerase IV mutations (Sulavik and Barg, 1998).
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1.10 Primary and Secondary Quinolone Targets
Resistance to quinolones develops in a step-wise manner. Addition mutations
accumulate within DNA gyrase or topoisomerase IV with each new bacterial
generation challenged. When topoisomerase IV was discovered as a second target
for quinolones in both Gram-negative and Gram-positive organisms, the question as
to whether DNA gyrase or topoisomerase IV was the primary quinolone target arose.
Mutation studies have indicated that in Gram-negative organisms such as E. coli,
DNA gyrase is the primary target (Heisig, 1996; Khodursky et al. 1995), because
mutations in gyrA appear before mutations in parC. Following the sequencing of
S. aureus topoisomerase IV by Ferrero et al (1994), the development of resistance
mutations in S. aureus was also investigated. Was there a different primary target in
Gram-positive organisms? The QRDRs of gyrA and grlA of resistant mutants
selected with ciprofloxacin in a step-wise manner, were amplified by PCR and
sequenced (Ferrero et al. 1995). The sequences revealed topoisomerase IV but not
DNA gyrase mutations in first-step mutants leading the authors to conclude that
topoisomerase IV is the primary target of quinolones in Gram-positive organisms.
Subsequently, a number of studies of other bacterial species and clinical isolates
confirmed this conclusion (Gonzalez et al. 1998; Ng et al. 1996; Tankovic et al.
1996).
However, this early work was done only with ciprofloxacin, an older quinolone that
is primarily active against Gram-negative organisms and has poorer activity against
Gram-positive organisms such as S. aureus (Al-Nawas and Shah, 1998; Dalhoff et al.
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1996). Some more recent studies indicate that other factors may also need to be
taken into account. For example, it is clear that although cross-resistance is observed
throughout the class of quinolone antibiotics, a mutation that confers high level
resistance to one quinolone may not confer the same degree of resistance to newer
quinolones (Schmitz et al. 1998; Takahashi et al. 1998; Takahata et al. 1996).
Recent work also indicates that gyrA and parC are dual and equal targets in
S. pneumoniae for sparfloxacin (Pan and Fisher, 1997), clinafloxacin (Pan and
Fisher, 1998) and several other quinolones (Varon et al. 1999), rather than one
enzyme being designated as the primary target. So far little work has been done to
investigate this result in other bacterial species with different quinolones.
1.11 Epidemiology ofpathogenic S. aureus
The spread of quinolone resistance has been predicted to be limited by the fact that
mutations conferring resistance are chromosomal rather than plasmid-encoded
(Smith, 1984). This means that a small number of strains may be responsible for
clonal spread of resistance since transfer between strains and species is restricted.
Flowever, there is still epidemic potential in such a spread if a resistant bacterium
such as S. aureus has multiple drug and antiseptic resistance genes enhancing
survival (Dalhoff, 1994). Indeed, one study found that resistance to perfloxacin, an
older quinolone rose as high as 99% in most hospitals in France during 1993
(Goldstein and Acar, 1995). As expected, the rate of resistance has been
demonstrated to be lower amongst community acquired isolates compared to
nosocomial pathogens that are subjected to more rigorous selective environmental
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pressures. However, despite current low levels of resistance the fact remains that
resistance to quinolones is increasing globally (Thomson, 1999) so the situation
requires continued monitoring and sensible strategies for resistance control.
/. 12 A Modelfor Studying In Vivo Quinolone Activity
Although the activity of all quinolones can be extensively studied in vitro it is often
difficult to know whether the resulting data is relevant to what happens in vivo.
Bacteria grown in the artificial, highly controlled environment of the laboratory may
not respond in the same way when subject to the rigorous stresses of the human body
where mutation pressures may become far greater. Quinolones also may have
different activity in vivo, where they may react with biological systems and
molecules in an unexpected manner. Indeed, the in vivo deficiency of oxygen
compared to the in vitro environment is one factor known to effect the therapeutic
activity of quinolones (Smith and Zeiler, 1998). The outcome of treatment cannot
therefore be easily predicted unless in vivo investigations are made during the
research and development stages of a new agent. Although simple dosing models are
used to determine preferred routes of administration and pharmacokinetic profile,
infection models are also useful. Many animal models have been developed to
emulate human infection. One such model is a murine subcutaneous abscess model
developed by Bunce et a! (1992). In this model mice are infected subcutaneously
with S. aureus to produce abscesses. They are then treated with antibiotic by
subcutaneous injection, and the efficacy of antibiotic therapy evaluated by
determining the viable count recoverable from abscesses after treatment. Previous
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studies with this model have indicated the need for adequate concentrations of
ciprofloxacin at the site of infection in order to inhibit bacteria and prevent the
development of resistance (Sulavik and Barg, 1998; Doss et al., 1995). This model
has fewer procedural difficulties than an invasive model such as the prosthetic
implant model of Cagni el al (1995) or the endocarditis model of Entenza et al
(1999). A neutropoenic thigh model has also been used to study the efficacy of
quinolones, including moxifloxacin, in vivo (Dalhoff, 1999). This is similar to the
subcutaneous abscess model, but takes into account the influence of immune status.
Since S. aureus is the most common cause of nosocomial wound infections, the
subcutaneous abscess model is considered to be particularly relevant to human
infection (Bunce et al. 1992). By investigating one or more of these models it
should be possible to predict the clinical progression of infection, resistance
development, and potentially toxic side-effects in humans that cannot be determined
from in vitro data alone.
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/. 13 Aims of This Thesis
• To investigate the mechanisms of action of moxifloxacin, a new
8-methoxyquinolone, against standard laboratory strains and clinical isolates of
S. aureus.
• To investigate the development of quinolone resistance in S. aureus conferred by
mutations in DNA gyrase, topoisomerase IV and an efflux system, and determine
the primary and secondary molecular targets ofmoxifloxacin.
• To investigate the bactericidal activity of moxifloxacin in a murine
staphylococcal abscess model, and make a comparison between the development
of resistance in vivo and in vitro.
• To investigate the efficacy of moxifloxacin against quinolone-resistant strains of
S. aureus with identified mutations, and determine the effect of these mutations
on the mechanisms of action.
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Chapter 2: Materials and Methods
2.1 Strains
Bacterial strains used in this project are listed in Table 2.1. All isolates were stored
at -70°C in nutrient broth containing 10% glycerol and were subcultured onto
Mueller Hinton agar (Oxoid, Basingstoke, UK) plates before use.
Table 2.1 : Standard and clinical strains used in this study.
Bacterial Strain Characteristics Source
S. aureus NCTC 6571 Laboratory Standard
S. aureus NCTC 8325/4 Laboratory Standard Dr C. Gemmel








S. aureus ED9 Clinical isolate
5. aureus E3T Laboratory Standard Dr I. Morrissey
E. coh NCTC 10418 Laboratory Standard
P. aeruginosa NCTC 662 Laboratory Standard
2.2 Media
All media powders were obtained from Oxoid (Basingstoke, UK) and made up with
distilled water according to the manufacturer's instructions. For double strength
media twice the given weight of powder was added to a single volume of water.
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Prior to use all media were sterilised by autoclaving at 121°C and 15psi for 15
minutes to destroy all vegetative cells and spores.
Media used in this study were Mueller Hinton agar (MHA), Nutrient Broth No. 2
(NB) and Brain Heart Infusion broth (BHI).
2.3 Materials
2.3.1 Antimicrobial Agents
Antimicrobial agents, manufacturers and solubility information are listed in Table
2.2. Fresh stock solutions of all antibiotics were prepared on the day of use.
Table 2.2 : Antimicrobial agents and their solvents
Antimicrobial Supplier Solvent
Moxifloxacin Bayer AG, Wuppertal, Germany Water
Ciprofloxacin Bayer pic, Newbury, UK. Water
Trovafloxacin Pfizer, Sandwich, UK 0.1M NaOH* and water
Grepafloxacin Glaxo Wellcome, UK Water
Sparfloxacin Dainippon, Japan 0.1M NaOH* and water
Tetracycline Sigma Chemicals, Poole, UK Water
Chloramphenicol Sigma Chemicals, Poole, UK 70% alcohol*: and water
*Enough to dissolve powder
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2.3.2 Chemicals and Buffers
All chemicals were purchased from Sigma Chemicals (Poole, UK) unless otherwise
stated and solutions made up with sterile distilled water. Saline was made up with
0.85% w/v NaCl and sterilised before use. Buffers were made according to the Data
for Biochemical Research (1974).
2.4 In Vitro Methods
2.4.1 Susceptibility Testing
Susceptibility testing to determine the minimum inhibitory concentrations (MICs) of
antibiotics was performed by the agar dilution method (British Society for
Antimicrobial Chemotherapy Working Party, 1991). Isolates were grown overnight
in lOmL of BHI at 37°C in a shaking incubator. Bacterial cultures were then diluted
to 10~4 in sterile saline and inoculated onto MHA plates containing serial doubling
dilutions of antibiotic with a multipoint inoculator (Denley, UK). Plates were
incubated overnight at 37°C. The MIC was defined as the lowest concentration of
antibiotic to fully inhibit bacterial growth. E. coli NCTC 10418, P. aeruginosa
NCTC 662, S. aureus NCTC 6571, S. aureus E3T and S. aureus ED3 were used as
control strains.
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2.4.2 Narrow Range MICs and the Effect of Reserpine
To determine precise concentrations of ciprofloxacin or moxifloxacin required for
mutant selection plates, further sensitivity testing was performed with modification
of the method described in section 2.4.1 as follows. A range of antibiotic
concentrations increasing by small increments from just below to just above the MIC
were investigated instead of doubling dilutions. In some experiments plates also
contained 10 or 20mg/L of reserpine in addition to antibiotic in order to determine
the effect of selective inhibition of efflux.
2.4.3 Viable Counts
Bacterial strains grown overnight in BHI were subcultured to log phase by adding
0.5mL to 9.5mL of BHI and incubating at 37°C with shaking for two hours. Serial
dilutions of 1 in 10 or 1 in 100 were made in sterile saline. This was achieved by
adding lmL of culture to 9.9mL or 0.1 mL of culture to 9.9mL of saline. Aliquots of
0.1mL from each dilution were evenly spread onto MHA plates with a sterile glass
spreader. Plates were allowed to dry on the bench for 30 minutes and then incubated
overnight at 37°C after which time the number of colony forming units (cfus) per
plate was determined with a colony counter (Anderman, Kingston-upon-Thames,
UK). The viable count in the undiluted culture was estimated by taking the dilution
factor into consideration.
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2.4.4 Optimum Bactericidal Concentration
In order to determine the optimum bactericidal concentration (OBC) of
moxifloxacin, dilutions of a stock solution of antibiotic made up to 4.8mL with
distilled water were added to 5mL aliquots of double strength BHI broth, to give
final concentrations in lOmLs of 0.01, 0.1, 1.0, 10 and lOOmg/L. All tubes were
warmed to 37°C for 15 minutes.
Bacteria were grown overnight in BHI, then subcultured to log phase and 0.2mL
added to each warmed tube containing moxifloxacin. After incubation for 3 hours at
37°C viable counts were determined as described in section 2.4.3.
2.4.5 Time-kill Kinetics
Bacteria were grown overnight in lOmL BHI broth and cultured to log phase in two
tubes as described in 2.4.3. One tube was centrifuged at 3000 rpm for 20 minutes,
the supernatant decanted, and the cell pellet resuspended in lOmLs sterile phosphate
buffered saline (PBS).
Three tubes were set up as follows. All contained sufficient moxifloxacin to give a
final concentration of lmg/L in lOmLs. Two tubes had 5mL of double strength BHI
broth added to them, and chloramphenicol was also added to one of these tubes to
give a concentration of 20mg/L in lOmLs. In the third tube double strength PBS was
substituted for BHI broth. The volume in each tube was made up to 9.8mLs with
sterile distilled water. Tubes were warmed to 37°C for 15 minutes before 0.2mL of
37
Chapter 2: Materials and Methods
log phase culture was added to each. All tubes were incubated for 3.5 hours at 37°C
and viable counts determined as described in section 2.4.3.
2.4.6 Selecting Quinolone-resistant Mutants
Bacteria were grown overnight in BHI and subcultured to late log phase by adding
0.5mL of overnight culture to 9.5mL of BHI and incubating at 37°C with shaking for
two hours. Quinolone-resistant mutants were selected by spreading 0.1 mL of log
phase bacterial culture (<1 x 101(l cfus) onto MHA plates containing moxifloxacin or
ciprofloxacin. The concentrations increased in small increments from the MIC
upwards, instead of multiples of the MIC suggested by Ferrero et al., (1995). All
plates were incubated for 72 hours at 37°C and the number of mutants per plate
recorded. Mutants were subcultured on MHA plates to check for purity prior to
storage at -70°C in 10% glycerol. Viable counts were performed simultaneously
with mutant selection so that mutation frequencies could be determined.
2.4.7 Genomic DIVA Extraction
Genomic DNA was extracted from bacterial cells by a rapid extraction method (Unal
et al. 1997). Bacteria were cultured overnight in lOmL of BHI broth and cells from
0.2mL aliquots pelleted by microfugation at 1300rpm for 30 seconds. Each cell
pellet was resuspended in 50pJL of lOOmg/L lysostaphin and incubated at 37°C for 10
minutes. Following incubation 50pJL of lOOmg/L proteinase K, and 150pL of 0.1 M
Tris buffer (pH 7.5) were added. The DNA extract mixture was incubated for a
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further 10 minutes at 37°C, followed by 5 minutes in a water bath at 100°C. Samples
were cooled on ice until required and 1 OjuL aliquots used in each PCR reaction
mixture.
2.4.8 Amplification of QRDRs by the Polymerase Chain Reaction
The quinolone resistance determining regions ofgyrA, gyrB and gr/A were amplified
by the polymerase chain reaction (PCR). The primers used for each PCR are shown
in Table 2.3 below. Primers for gyrA and grlA were designed using Primer3
(http://www.genome.wi.mit.edu/cgi-bin/primer) based on published gene sequences
(Ferrero et al. 1994; Margerrison and Hopewell, 1992) and synthesized by
Immunogen International Ltd (Sunderland, UK). The primers used for amplification
of the gyrB fragment had previously been described by Takahashi et aI (1998).
Table 2.3 : PCR primers
Gene PCR Primers Sequence Reference
(Accession no.)
gyrA 5' -GACTTCTAAGCGCTGTGAAC (Margerrison and
(M86227) 3' -AAGTTACCTTGGCCATCAAC Hopewell, 1992)
grlA 5' -TGTTTTAGGTGATCGCTTTGG (Ferrero et al. 1994)
(L25288) 3' -GGCAATACCATTGGTTCGAG
gyrB 5' -AAGTCGCACGTACAGTGGTT (Takahashi et al. 1998)
3' -CTGTACCAAATGCTGTGATC
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PCR reactions were performed in a total volume of lOOpL containing all reagents as
shown in Table 2.4. A negative control consisting of the PCR reaction mixture
without DNA template was included for each run to detect bacterial contamination.
The content of each tube was overlaid with 50pL of mineral oil to prevent
evaporation of PCR reaction components.
Table 2.4 : Components of PCR reaction mixture
Stock Final Volume
Component Concentration Concentration (pL)
5'Primer lOpmol/pL lOpmol 1
3'Primer lOpmol/pL lOpmol 1
dNTPs* 4mM 200pM 5
Tris-HCl/KCl** 200mM Tris/ 20mM Tris/ 10
500mM KC1 50mM KC1
MgCh 50mM 2.5mM 5
milliQ H2O - - 66
DNA extract - - 10
Taq polymerase 1 Unit/pL 2 Units 2
* Boehringer Mannheim, Lewes, E. Sussex
** Promega, Southampton
Thermal cycling was performed on a Techne PHC-2 Dri-Block Cycler (Cambridge
Bioscience, Cambridge) with an initial denaturation step of 94°C for 30 seconds,
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55°C for 30 seconds and 72°C for 10 minutes. This was followed by 30 cycles of 1
minute at 90°C for denaturation, 2 minutes at 42°C for annealing and 3 minutes at
72°C for polymerisation. The final extension step was 5 minutes at 72°C.
2.4.9 Rapid Typing by Repetitive Extragenic Palindromic-PCR
Rapid typing by repetitive extragenic palindromic-PCR (Rep-PCR) was performed
on crude DNA extracts obtained using the method described in section 2.4.7. Each
reaction mixture contained 10p.L of template DNA. PCR primers REPIR-Dt and
REP2-Dt (Versalovic et al. 1993; Versalovic et al. 1991) were used at a
concentration of 50pmol, with dNTPs at a concentration of 1.25mM in a total
reaction mixture volume of lOOpL. All other components of the PCR reaction were
used at the concentrations shown in Table 2.4. PCR was performed employing the
cycling parameters described by Versalovic et al., (1991) beginning with an initial
denaturation step of 95°C for 7 minutes. This was followed by 30 cycles of
denaturation at 90°C for 30 seconds, annealing at 40°C for 1 minute and extension at
65°C for 8 minutes. A single final extension step of 65°C for 16 minutes concluded
the cycling program.
2.4.10 Visualisation of PCR Products by Agarose Gel Electrophoresis
PCR products were visualised by electrophoresis of samples on a 2% w/v agarose
gel. Electrophoresis grade agarose (Gibco BRL, Life Technologies, Paisley, UK)
was dissolved in 40mM Tris-acetic acid/2mM EDTA, pH 8.0 (TAE) buffer.
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Ethidium bromide stock was added to the gel giving a final concentration of
0.5mg/L. Electrophoresis was carried out in a tank containing TAE as running
buffer. Each 10p.L sample of PCR product was mixed with 2|uL of loading buffer
consisting of 0.25% w/v bromophenol blue, 0.25% w/v xylene cyanol, and 30% w/v
sucrose. A standard molecular weight marker - X DNA cut with Hindlll or lOObp
ladder (Gibco BRL) - was also loaded in one lane on every gel. Samples were
electrophoresed at 20mA (100V) until the migrating loading buffer fronts had moved
two thirds of the way down the gel. After electrophoresis, banding patterns could be
observed and recorded by placing the gel on a TM 40E UV transilluminator (UV
Products, Cambridge; UV wavelength 302nm) and photographing with a Polaroid
camera fitted with an orange filter.
2.4.11 Purification and Quantification of PCR Products
PCR products were purified using a QIAquick PCR purification kit (QUIAGEN Ltd,
Crawley, UK) according to the manufacturer's instructions. The purified PCR
products were eluted from the column into 30p.L of elution buffer instead of lOOpL
in order to concentrate the DNA. The approximate amount of DNA per 30pL
sample was quantified after electrophoresis on a 2% w/v agarose gel by comparing
the brightness of the sample bands with neat and diluted samples of pUC19 (Gibco
BRL), a standard marker known to have 250ng ofDNA per microlitre.
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2.4.12 Automatic DNA Sequencing
The primers used for PCR amplification were also used for DNA sequencing, with
3.2pmol of primer required per sequencing sample. The DNA content of each
sample to be sequenced was determined as described in section 2.4.11 to ensure that
it contained 30-90ng of DNA. An ABI Prism dRhodamine terminator cycle
sequencing ready reaction kit (PE Applied Biosystems, Warrington, UK) was used
following the manufacturer's instructions and sequencing cycles were performed on
a Techne Cyclogene Dri-Block Thermal Cycler (Cambridge Biosciences). The cycle
sequencing program consisting of 25 repetitions of 96°C for 30 seconds, 45°C for 15
seconds and 60°C for 4 minutes. Extension products were purified by the rapid
ethanol precipitation method suggested by the sequencing kit manufacturer.
Automatic DNA sequencing was determined by Edman degradation performed on an
Applied Biosystems Procise Sequencer. A sample densitometry trace showing a
typical sequence obtained from automatic sequencing of the QRDR is given in
Appendix VII. All results were compared to the published sequences detailed in
Table 2.3, by the BLAST online search facility (http://www.ncbi.nlm.nih.gov/cgi-
bin/BLAST/nph-blast?Jform=0) and differences in sequences noted.
2.4.13 Radio-labelled Moxifloxacin Uptake Assay
The uptake of [l4C]-moxifloxacin was assayed by an established method (Kaatz and
Seo, 1995; Kaatz et al. 1993). Bacterial strains were grown overnight in BHI and
then subcultured to log phase in 20mL of BHI. Cells were concentrated by
centrifuging at 3000rpm at 4°C for 20 minutes. The supernatant was removed and
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cell pellets were resuspended in lmL of Bill. Ahquots of 790pL were dispensed
into sterile eppendorf tubes and diluted 1 in 5 by adding 200pL of fresh BHI. All
samples were stored on ice until required.
A stock solution was prepared containing lOOmg/L of [!4C]-moxifioxacin with an
_ ... , : _ :, _ _ jo c o o i ia _ i-- _i- a aaa x 11 -,, .* 4 ia.,t _ .1
activity 01 j.ooRDq. nacn u.yyuiiiL, ecu suspension was exposeu to iwpL 01 ullS
stock giving a final moxifloxacin challenge concentration of lmg/L (2.94kBq). All
suspensions were placed in a water bath at 37°C for the duration of the assay.
Aliquots of 40pL were removed at timed intervals of 0, 1.5, 3, 4.5, 6, 10, 15, 20, 25
and 30 minutes after the radio-labelled moxifloxacin was added. In some
experiments carbony! cyanide w-chlorophenylhydrazone (CCCP) at a final
concentration of lOOpM was added after 15 minutes to inhibit the proton motive
force.
Each 40pL sample was filtered through a 13mm, 0.45pm GN-6 Metncel Membrane
disc filter (Pall Geiman Sciences) and then washed through with 6mL of sterile
saline. Filters were allowed to dry and then placed in scintillation vials (Canberra
Packard, Zurich, Switzerland) to which 1 niL of scintillation fluid (Canberra Packard)
was added. The activity of each sample, given as counts per minute, was determined
by a scintillation counter (Canberra Packard).
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2.4.14 Radio-labelled Moxifloxacin Efflux Assay
The efflux of [l4C]-moxifloxacm from bacterial cells was determined by a washing
assay as follows. Strains were cultured to log phase and concentrated 20-fold as
described in section 2.4.13. Each sample was challenged with moxifloxacin as
described previously, and then incubated at 37°C for 10 minutes. Aliquots were
removed from each test sample for filtration as previously described, and then each
sample was washed and resuspended in fresh BHI. The washing step was repeated at
least 6 times for each strain, and 40juL samples were removed and filtered at every
step. Simultaneously, I OjuL aliquots were also removed at each washing step so that
the viable count could be determined (see section 2.4.3). All filters were dried and
the activity determined by scintillation counting as before.
2.5 In Vivo Methods
2.5.1 Induction of Subcutaneous Abscesses in a Mouse Model
The in vivo efficacy of moxifloxacin against S. aureus was investigated using a
murine subcutaneous abscess model (Bunce et al. 1992). Eight week old male C3H
mice were divided into cohorts of 10 animals. Each cohort was allocated a specific
ear marking with all animals within the cohort receiving the same mark. The flanks
of all animals were shaved and the weights of all animals were noted.
Bacteria were cultured overnight in lOmL of BHI broth and then grown to log phase
and an optical density (590nm) of 0.2, equivalent to 10 cfu/mL as previously
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determined from a standard laboratory curve. A 500jj.L culture sample was mixed
with 310pL of BHI broth and 190pL of Cytodex-1 microcarrier beads. Each mouse
was injected subcutaneously on the right flank with 200pL of this mixture with a
ImL syringe (Beckton-Dickinson UK Ltd, Cowley, Oxford) and a 25-gauge syringe.
Care was taken to ensure that the bevel of the needle faced upwards when the
injection was made to ensure localised inoculation and consistency of injections. All
animals were left for 48 hours to allow abscesses to develop fully.
2.5.2 Establishing Moxifloxacin Concentrations in Serum and Abscesses
In order to establish the concentrations of moxifloxacin achievable in subcutaneous
abscesses, two cohorts of mice were infected with S. aureus NCTC 8325/4 as
described previously. After 48 hours, all the animals were injected with 200p.L of a
range of moxifloxacin concentrations (dissolved in sterile PBS) on the left flank and
30 minutes later ocular blood samples were taken. The animals were sacrificed after
three hours and the abscesses excised. All abscess material was frozen in PBS and
sent together with the blood samples to Caroline Tobin (Southmead Hospital,
Bristol) for determination of moxifloxacin concentration by high performance liquid
chromatography (HPLC) analysis. Plotting the concentration detected by HPLC
versus the dose concentration given to the animal produced a standard curve which
could be used to determine the correct dose required to produce specific
concentrations within an abscess.
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2.5.3 Determining Bacterial Survival from Subcutaneous Abscesses
Subcutaneous staphylococcal abscesses were established in four cohorts of mice as
described in section 2.5.1. Three cohorts were treated with 200]uL of moxifloxacin
(dissolved in sterile PBS) at a concentration determined from a standard curve to
reach 1, 2 or 4 times the MIC ofNCTC 8325/4 within the abscesses. The mice were
dosed every two hours for 24 hours, with all 10 animals within a cohort receiving the
same dose of moxifloxacin. As a control a fourth cohort was treated in the same
manner with 200pL of PBS alone. The animals were sacrificed an hour after the
final injection, and the abscesses excised and placed into PBS. All of the abscesses
were homogenised and the homogenate supplemented with PBS to give a total
volume of lmL. The homogenate was diluted in sterile saline and viable counts
determined as described previously (section 2.4.3).
2.5.4 Selection of In vivo Mutants
The possibility ofmoxifloxacin selecting for quinolone-resistant mutants in vivo was
investigated by inoculating agar plates containing moxifloxacin with 0.1mL of neat
abscess homogenate as described in section 2.4.6. The number of mutants per plate
was counted after 72 hours of incubation at 37°C and mutation frequencies were
determined based on the viable count. Mutants were subcultured for purity and
stored at -70°C in 10% glycerol. The Rep-PCR typing method described in section
2.4.9 was employed to confirm that mutants recovered were not contaminants.
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Historically the quinolones have been used to target Gram-negative bacteria and have
had poor activity against Gram-positive bacteria (Smith and Zeiler, 1998).
Moxifloxacin is a new 8-methoxyquinolone with enhanced activity against Gram-
positive organisms compared to older agents such as ciprofloxacin (Alcala et al.
1999; Boswell et al. 1999; Al-Nawas and Shah, 1998; Bauernfeind, 1997; Dalhoff et
al. 1996). By determining the OBC and examining the time-kill kinetics of this drug
against standard laboratory strains and clinical isolates of S. aureus, an assessment of
in vitro efficacy can be made.
3.1 Susceptibility Testing
Three well characterised standard laboratory strains and four clinical strains of
S. aureus were chosen for this project. Clinical strains ED3 and ED5 had previously
been identified as ciprofloxacin and methicillin resistant, while strains ED7 and ED9
were ciprofloxacin and methicillin sensitive. The MICs of all strains are shown in
Table 3.1. All standard S. aureus strains were sensitive to moxifloxacin,
ciprofloxacin and chloramphenicol. The E. co/i and P. aeruginosa control strains
were also sensitive to ciprofloxacin, but were resistant to chloramphenicol.
P. aeruginosa was resistant to moxifloxacin, with an MIC of 1 .Omg/L.
48
Chapter 3: Results - Mechanisms ofAction
Clinical isolates ED3 and ED5 were resistant to moxifloxacin and to ciprofloxacin
compared to the control strains. Isolates ED7 and ED9 were sensitive to both
moxifloxacin and ciprofloxacin, although ED9 was slightly less sensitive to
ciprofloxacin than ED7 (MIC of 0.12mg/L compared to 0.03mg/L). All clinical
isolates were sensitive to chloramphenicol.
Table 3.1: MICs of 9 strains used in this study
MIC in (mg/L)
Strain Moxifloxacin Ciprofloxacin Chloramphenicol
S. aureus NCTC 6571 0.03 0.03 2
S. aureus NCTC 8325/4 0.06 0.50 2
S. aureus ED3 2.00 >8.00 4
S. aureus ED5 2.00 >8.00 4
S. aureus ED7 0.06 0.03 4
S. aureus ED9 0.06 0.12 4
S. aureus E3T 0.03 0.03 2
E. coh NCTC 10418 0.03 <0.03 >32
P. aeruginosa NCTC 662 1.00 0 12 >32
3.2 The Optimum Bactericidal Concentration ofMoxifloxacin
The OBC is the minimum concentration of quinolone giving the maximum killing
effect, above which killing decreases due to inhibition of RNA synthesis (Smith,
1984). The OBC of moxifloxacin was determined for laboratory standards NCTC
6571, 8325/4 and E3T, by challenging log phase cultures with increasing
concentrations of moxifloxacin for three hours. Figure 3.1 shows the three dose
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response curves of these strains when challenged with moxifloxacin.
Concentration-dependent killing was exhibited by moxifloxacin against all strains,
however the classic biphasic killing curve described by Smith (1984) was not
observed. This means that there is not a true 'optimum' bactericidal concentration of
moxifloxacin, although a concentration more accurately described as the 'maximum'
bactericidal concentration is easily observed. This concentration ofmoxifloxacin for
all strains was approximately l.Omg/L, as indicated by an arrow on the figure.
Figure 3.1: Determining the OBC of moxifloxacin against standard laboratory
strains
-•-NCTC 6571 -#-NCTC 8325/4 -B-E3T
Concentration (mg/L)
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3.3 Mechanisms ofMoxifloxacin Action Against S. aureus
Having established that the maximum killing activity of moxifloxacin is achieved at
l.Omg/L against standard laboratory strains of S. aureus, this concentration was used
to challenge cultures under different growth conditions in order to investigate the
presence of different mechanisms of quinolone action (Smith, 1984). Bacteria were
subjected to moxifloxacin challenge in broth with or without the protein synthesis
inhibitor chloramphenicol, or in PBS. Samples were removed at 30 minute intervals
and the number of surviving cfus determined.
Figure 3.2: Time-kill kinetics of lmg/L of moxifloxacin against S. aureus
NCTC 6571 in NB, PBS, or NB containing 20mg/L chloramphenicol
NB —PBS —NB+Chloramphenicol
Time (minutes)
The results for standard strain NCTC 6571 are shown in Figure 3.2. Moxifloxacin
showed good bactericidal activity against this strain at l.Omg/L with less than 1%
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survival by 30 minutes after challenge. Inhibition of protein synthesis by the
addition of a bacteriostatic concentration of chloramphenicol did not completely
remove the killing activity of moxifloxacin. Less than 10% survival was observed
after 180 minutes when chloramphenicol was included. Similarly, inhibiting cell
division by challenging the strain in PBS rather than nutrient broth did not
completely remove the killing activity. Less than 10% survival was observed 150
minutes after challenge. Similar results were observed with strains NCTC 8325/4
and E3T as shown in Figures 3.3 and 3.4. Moxifloxacin showed good bactericidal
activity against both strains at 1.0mg/L, and also retained activity against both strains
even if protein synthesis and cell division were inhibited.
Figure 3.3: Time-kill kinetics of lmg/L of moxifloxacin against S. aureus NCTC
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Figure 3.4: Time-kill kinetics of lmg/L of moxifloxacin against S. aureus E3T in
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3.4 Activity ofMoxifloxacin Against Clinical S. aureus Isolates
Although the mechanisms of action may be easy to demonstrate against standard
sensitive laboratory strains, it is not clear whether the same results will be obtained if
clinical isolates are challenged instead. Moxifloxacin at l.Omg/L was used to
challenge four clinical isolates of S. aureus. Log phase cultures of each strain were
exposed to this concentration for 210 minutes at 37°C, and the number of viable
colonies determined at 30 minute intervals.
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3.4.1 Clinical Strains ED3 and ED5
Since l.Omg/L is equivalent to only half the MIC for strains ED3 and ED5, this
concentration was not bactericidal. These strains were therefore also challenged with
4, 8 and 16mg/L (2, 4 and 8 times MIC). The results for strain ED3, which is both
quinolone and methicillin resistant, are shown in Figure 3.5.
Moxifloxacin is not bactericidal against this strain at l.Omg/L - in fact the bacterial
population is able to multiply. JTowever, good bactericidal activity is restored at
4mg/L and higher concentrations, with survival decreasing to less than 1% between
60 and 90 minutes after challenge. A similar result was observed with strain ED5,
which is also quinolone and methicillin resistant.
Figure 3.5: Clinical isolate ED3 challenged with 1, 4, 8 or 16mg/L moxifloxacin
l/2xMIC -#-2xMIC —•~4xMIC -±-8xMIC
1000
0.0001
0 30 60 90 120 150 180 210
Time (minutes)
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Figure 3.6: Clinical isolate ED5 challenged with 1, 4, 8 or 16mg/L moxifloxacin
l/2xMIC 2xMIC -»-4xMIC -A-8xMIC
Time (minutes)
The results in Figure 3.6 show that 1 .Omg/L is not bactericidal against ED5, although
killing is restored at 4.Omg/L (2 times MIC) with less than 1% survival after 90
minutes.
3.4.2 Clinical Strains ED7 and ED9
Two other clinical strains were challenged with 1.Omg/L of moxifloxacin. Strains
ED7 and ED9 were quinolone and methicillin sensitive. Figure 3.7 shows the effect
of this concentration on both strains. Moxifloxacin showed significant bactericidal
activity at 1.Omg/L against both of these strains although the rate of killing was
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Figure 3.7: Clinical isolates ED7 and ED9 challenged with lmg/L moxifloxacin
ED7 —ED9
Time (minutes)
slower than previously observed against standard laboratory strains (Figures
3.2 - 3.4). Survival dropped to below 1% between 60 and 90 minutes after challenge
of strain ED7, and between 120 and 150 minutes after challenge of strain ED9.
3.5 Time-kill Kinetics ofMoxifloxacin Against Clinical Strains
The mechanisms of action of moxifloxacin against these four clinical strains of
S. aureus were investigated at l.Omg/L to determine whether the different resistance
profiles had any effect on the mechanisms of action.
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3.5.1 Mechanisms of Action Against ED3 and ED5
Resistant clinical isolates ED3 and ED5 were challenged with I.Omg/L of
moxifloxacin in nutrient broth with or without chloramphenicol, or in PBS in the
same manner as standard laboratory strains. The results are shown in Figures 3.8
and 3.9.
No killing activity is observed against either strain in nutrient broth alone. The
addition of chloramphenicol does not have any effect on the killing rate either, with
similar growth rates observed with and without this inhibitor. These results may be
predicted by the fact that neither of these strains is sensitive to moxifloxacin at
1 .Omg/L, which is only half the MIC.
Figure 3.8: Time-kill kinetics of lmg/L of moxifloxacin against ED3 in NB, PBS,
or NB containing 20mg/L chloramphenicol
9 NB ♦ PBS NB+Chloramphenicol
Time (minutes)
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Figure 3.9: Time-kill kinetics of 1 mg/L of moxifloxacin against ED5 in NB, PBS,
or NB containing 20mg/L chloramphenicol
NB ♦ PBS —■—NB+Chloramphenicol
Time (minutes)
Although both strains have less sensitivity to chloramphenicol than the standard
laboratory strains, this difference is not sufficient to have an effect since the
bacteriostatic concentration used was 20mg/L.
However, the presence or absence of active cell division seems to have some
influence on the quinolone killing of these resistant strains. Both EDS and ED5 were
killed by moxifloxacin at l.Omg/L when exposed in PBS rather than nutrient broth.
Survival of strain ED3 decreased to approximately 1% after 210 minutes, while ED5
was better able to survive with approximately 40% of cfus surviving to 210 minutes.
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3.5.2 Mechanisms of Action Against ED7 and ED9
The mechanisms of action against clinical isolates ED7 and ED9, were investigated.
Unlike sensitive laboratory strains that are specifically chosen as standards because
of their sensitive characteristics, these clinical strains may carry random mutations in
a wide variety of genes. Studying such strains isolated from infected patients may
give a more realistic representation of the efficacy that moxifloxacin is likely to have
against clinical pathogens, compared to standard laboratory strains which may not be
representative of pathogenic strains.
Figure 3.10 shows the time-kill kinetics obtained by challenging strain ED7 with
1 .Omg/L ofmoxifloxacin. As with the standard laboratory strains, ED7 is quickly
Figure 3.10: Time-kill kinetics of lmg/L of moxifloxacin against ED7 in NB,
PBS, or NB containing 20mg/L chloramphenicol
t NB ♦ PBS -■-NB+Chloramphenicol
Time (minutes)
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killed by l.Omg/L ofmoxifloxacin in nutrient broth, and up to 97% of cfus are killed
if a bacteriostatic concentration of chloramphenicol is also present. However,
suspending the culture in PBS to prevent cell division prior to challenge with
quinolone seems to negate any killing mechanisms otherwise present. When
exposed to moxifloxacin in PBS no killing occurred. This seems to be the opposite
result to those obtained with strains ED3 and ED5.
The results for strain ED9, shown in Figure 3.11, are very similar to those obtained
for ED7. This strain is killed in nutrient broth alone with less than 1% survival by 90
minutes, and is also killed in the presence of chloramphenicol with less than 10% of
cfus surviving by 210 minutes. However, no killing is observed when the ED9 was
incubated with moxifloxacin in PBS.
Figure 3.11: Time-kill kinetics of lmg/L of moxifloxacin against ED9 in NB,
PBS, or NB containing 20mg/L chloramphenicol
9 NB ♦ PBS NB+Chloramphenicol
Time (minutes)
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Chapter 4: Results - Mutations in DNA gyrase and
Topoisomerase IV
Quinolones interact with the transient cleavable complexes formed between DNA
gyrase or topoisomerase IV, and DNA in an undetermined manner, resulting in lethal
breaks in the DNA strands (Maxwell and Critchlow, 1998). Resistance to the
quinolones can arise through a variety of point mutations at hotspots located
primarily within the QRDRs ofgyrA or grIA (Everett and Piddock, 1998). Studies of
the development of these mutations have indicated that DNA gyrase is the primary
target of quinolones in Gram-negative organisms. In contrast, topoisomerase IV is
the proposed primary target in Gram-positive organisms, based primarily on work
with ciprofloxacin (Ferrero et al. 1995). Ciprofloxacin has good activity against
Gram-negative organisms but relatively poor activity against Gram-positive
organisms. Characterisation of the QRDRs of sequentially selected mutants of
moxifloxacin provides an opportunity to investigate the hypothesis that new anti-
Gram-positive quinolones may cause different mutational changes and have different
molecular targets to older agents.
4.1 Mutation Frequencies and Sensitivity to Moxifloxacin
Moxifloxacin-resistant mutants of S. aureus strain NCTC 8325/4 were selected by
spreading 100pL of culture onto plates containing concentrations of moxifloxacin
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increasing by small increments above the MIC of the parent. The viable count of
mutants per plate on plates with less than 50 cfus was determined at each
concentration, and a viable count was performed in parallel on non-selective plates
so that mutation frequencies could be determined.
4.1.1 First-step Moxifloxacin-Selected Mutants
Following the mutant selection process, randomly chosen strains were isolated from
each plate. Each strain was subcultured onto a fresh MHA plate to establish purity,
then designated with a culture collection number and stored at -70°C prior to
sensitivity testing. All strains were subcultured from storage and the MICs of
moxifloxacin determined by agar dilution using a narrow range of concentrations.
The MICs of 86 first-step mutants, their fold increases in resistance and the
concentrations at which they were selected are shown in Appendix I. The parent
strain had an MIC of 0.05mg/L and resistant mutants could be isolated on plates
containing 0.125, 0.150, 0.175 and 0.200mg/L of moxifloxacin, but all growth was
inhibited at higher concentrations. The majority of strains tested showed decreased
sensitivity to moxifloxacin, with MICs between 1.5 and 5 fold higher than the parent
strain. Strains were most commonly found to have an MIC of 0.100 or 0.125 mg/L
(27 and 37 strains respectively), equivalent to a 2 or 2.5 fold decrease in sensitivity
compared to strain NCTC 8325/4. A small number of strains were found to have
MICs with an increase of only 1.5 fold or less. These strains were not considered to
be true resistant mutants.
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Eleven strains with moxifloxacin MICs of 0.125mg/L were chosen at random for
further study. These strains, highlighted in grey in Appendix I, are shown in
Table 4.1 along with the parent strain NCTC 8325/4. Eight of these strains were
selected as first-step parent strains from which second generation mutants were
selected. These parent strains are shown below the double line in Table 4.1.
Table 4.1: First-step moxifloxacin-selected mutants chosen for further study
Isolate Selection Concentration MIC
Number (mg/L) (mg/L)
NCTC 8325/4* - 0.05













4.1.2 Second-step Moxifloxacin-Selected Mutants
The MICs of 49 second-step mutants, their parent strains, increases in resistance and
the concentrations at which they were selected are shown in Appendix II. Resistant
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strains could be isolated on plates containing up to 0.8mg/L ofmoxifloxacin. All the
strains tested showed decreased sensitivity to moxifloxacin, with MICs increasing by
4 to 40 fold compared to the primary parent NCTC 8325/4 (1.5 to 16 fold higher than
their first-step parent strains). Strains were most commonly found to have an MIC of
0.8mg/L (22 strains), equivalent to a 16 fold increase in MIC compared to strain
NCTC 8325/4. Four strains with MICs of 0.8mg/L, were selected as parent strains
for the next generation ofmutants. These strains (highlighted in grey in Appendix II)
are shown in Table 4.2.
Table 4.2: Second-step moxifloxacin-selected mutants chosen for further study
Parent Isolate Selection Concentration MIC
Strain Number (mg/L) (mg/L)
ED223 ED261 0.4 0.8
ED229 ED266 0.4 0.8
ED267 0.4 0.8
ED268 0.4 0.8
4.1.3 Third-step Moxifloxacin-Selected Mutants
The MICs of 62 third-step mutants, their parent strains, increases in resistance and
the concentrations at which they were selected are shown in Appendix III. Resistant
strains could be isolated on plates containing up to 4.2mg/L of moxifloxacin. All the
strains tested showed decreased sensitivity to moxifloxacin, with MTCs increasing by
20 to 90 fold compared to the primary parent NCTC 8325/4 (1.3 to 5.6 fold higher
than their second-step parent strains). Strains were most commonly found to have an
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MIC of 4.25 - 4.50mg/L (25 strains), equivalent to an MIC 85 or 90 times higher
than the primary parent strain NCTC 8325/4. Five strains with MICs of 4.25 -
4.5mg/L, were selected for further investigation. These strains are highlighted in
grey in Appendix III. Viable counts and mutation frequencies of first-, second- and
third-step mutants were determined. The mutation frequency was calculated with the
formula mf= n / vca, where mf is the mutation frequency, n is the number ofmutants
on a plate and vca is the viable count of cfus per 100pL aliquot determined from the
non-selective plates. Table 4.3 shows the mean viable counts, mean mutant counts
and mutation frequencies of each mutant selection step.
Table 4.3: Mean mutation frequencies of all parent strains
Parent Mutation Mean Viable Mean Mutant Mutation
Strain Step Count/1OOpL Count/lOOpL Frequency
NCTC 8325/4 1st Step 9.3 x 10 21.5 2.3 x 10"7
ED223 2nd Step 6.78 x 1010 2.67 3.9 x 10"11
ED229 2nd Step 3.96 x 1010 3.33 8.4 x 10""
ED268 3rd Step 5.9 x 1010 4.83 8.2 x 10""
It can been seen from the table that mutants are selected less readily with increasing
mutant generations i.e. as strains become more resistant it is harder to select still
higher levels of resistance. However, the mean viable counts were surprisingly high
for the second and third mutation steps (around 1010 compared to 107 for the first
mutation step), and this may explain why the mutation frequencies seemed to be
unusually low for these strains.
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4.2 Characterisation ofMoxifloxacin-SelectedMutant Strains
Five strains from each mutant generation were chosen for further investigation by
PCR amplification and DNA sequencing of the QRDRs of the gyrA and grlA genes.
After each mutation step it was clear that mutants with specific levels of resistance
were more commonly selected. Strains for further investigation were therefore
chosen from these modal groups.


































First-step mutants with an MIC of moxifloxacin of 0.125mg/L, second-step mutants
with an MIC of 0.8mg/L and third-step mutants with an MIC of 4.25 - 4.5mg/L were
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chosen. Figure 4.1 gives a schematic representation of the relationship between the
16 chosen strains.
4.2.1 Sensitivities of Moxifloxacin-Selected Mutants to Other Quinolones
The sensitivities of strain NCTC 8325/4 and the 15 resistant strains to three other
quinolones were established. MICs were determined by the standard doubling
dilution method (see 2.4.1). Ciprofloxacin is an older quinolone with good activity
against Gram-negative organisms, while sparfloxacin and trovafloxacin are newer
agents developed primarily to target Gram-positive organisms. The sensitivities of
all 16 strains to these three agents as well as moxifloxacin are shown in Table 4.4.
The MICs increased with each consecutive generation of mutants for all four
quinolones tested. Interestingly, although all five mutants within each generation
were found to have the same MIC ofmoxifloxacin, this was not always the case with
the other agents tested. From Table 4.4 it can be seen that ciprofloxacin MICs varied
by one dilution for first-step mutants, and two dilutions for second-step mutants
(MIC increase of 2 - 4 fold higher than NCTC 8325/4). The breakpoint sensitivity
concentration of ciprofloxacin for S. aureus, above which organisms are classed as
clinically resistant, is 2mg/L (British Society for Antimicrobial Chemotherapy
Working Party, 1991). Clinically significant levels of resistance were therefore
determined in two out of five second-step mutants (ED258 and ED261) that had
MICs of 8mg/L, and all third-step mutants had high levels of resistance with MICs
32mg/L.
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Table 4.4: MICs of four quinolones for moxifloxacin-selected resistant strains
S. aureus MICs in mg/L
strain Ciprofloxacin Sparfloxacin Trovafloxacin Moxifloxacin
NCTC 8325/4 0.5 0.06 0.06 0.06
First-step
ED 170 2 0.25 0.12 0.12
ED209 1 0.06 0.06 0.12
ED216 2 0.06 0.12 0.12
ED223 2 0.25 0.25 0.12
ED229 1 0.06 0.12 0.12
Second-step
ED258 8 1 1 1
ED261 8 1 1 1
ED268 2 1 0.25 1
ED276 2 1 0.25 1
ED277 2 1 0.5 1
Third-step
ED357 32 16 4 8
ED360 32 16 4 8
ED375 32 16 4 8
ED377 32 16 4 8
ED385 32 16 4 8
First-step mutants were more sensitive to sparfloxacin than to ciprofloxacin or
moxifloxacin (Table 4.4), with only two strains (EDI70 and ED223) showing
increases in MIC (4 fold). Both strains with increased MICs of sparfloxacin also had
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increased MICs of ciprofloxacin. Strains ED209, ED216 and ED229 were as
sensitive to sparfloxacin as the parent strain. All second-step and third-step mutants
were equally resistant to sparfloxacin (MICs of 1.0 and 16mg/L respectively).
Although a breakpoint value is not yet available for sparfloxacin, all third generation
strains have sufficiently high MICs that their resistance levels may be considered
clinically relevant.
Overall, trovafloxacin MICs were lower compared to the other three quinolones
(Table 4.4). Similar to sparfloxacin, strains ED 170 and ED223 showed an increase
in resistance (2 and 4 fold respectively). The other three first-step mutants were fully
sensitive to trovafloxacin. The MICs of second-step mutants correlated closely with
ciprofloxacin MICs: strains ED258 and ED261 had higher MICs (l.Omg/L) than the
other three strains. The MIC of all third-step mutants was 4.0mg/L, constituting a
smaller change in sensitivity from primary parent to third generation mutants than
was observed for any of the other quinolones. Although breakpoints are currently
unavailable for trovafloxacin, these third-step strains are likely to be classified as
clinically resistant.
4.2.2 Strain Typing by Rep-PCR
In order to ascertain that all mutant strains were directly related to the parent strain
NCTC 8325/4 and to exclude the possibility of environmental contamination, the
strains were examined using a rapid PCR-based typing method (section 2.4.9) and
compared to a number of control organisms. In Figure 4.2 the control organisms
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S. aureus NCTC 6571, NCTC 8325/4, E3T, ED3, ED5, E. coli NCTC 104018 and
P. aeruginosa NCTC 662 are shown in lanes 2 to 8 on each gel. Lane 1 contains the
standard lOObp ladder marker. Distinct banding patterns are observed for each
organism and strain. The banding patterns for ED3 and ED5 appear to be the same,
indicating that they may be clones with the same origin (i.e. from the same patient).
Figure 4.2: Rapid typing patterns generated by Rep-PCR
2072
1500
(a) Second-step Mutants (b) Third-step Mutants
The gels in Figure 4.2 show the Rep-PCR patterns for second-step mutants (a) and
third-step mutants (b) in lanes 9 to 13. It is clear from the banding patterns of the
control strains that this typing method is able to discriminate between different
strains of S. aureus as well as different organisms. The parent strain S. aureus
NCTC 8325/4 has a distinct banding pattern from all other strains tested. The mutant
strains have identical banding patterns to parent strain NCTC 8325/4 and to each
other. All first-step mutants also had the same banding pattern.
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4.2.3 QRDR Analysis
The DNA extraction and PCR protocols described in section 2.4 were tested with
five S. aureus strains and four negative controls to verify amplification of the correct
size ofDNA fragment. Fragment sizes of 374 bases for gyrA and 434 bases for grlA
gene were confirmed against a standard 100 base pair ladder. The results are shown
in Figure 4.3. The brightest bands of the 100 base pair ladder correspond to
fragments of 2072, 1500 and 600 bases (read top to bottom). PCR products
amplified with gyrA primers are to the left of the 100 base pair ladder (lane 10), and
products amplified with grlA primers are shown to the right.
Figure 4.3: Confirmation ofgyrA and grlA fragment sizes
Lanes 1 to 5 show the gyrA PCR products from S. aureus strains NCTC 6571, NCTC
8325/4, E3T, ED3 and ED5 respectively. Bands of the expected size (between 300
and 400 bases) were observed for all strains except for E3T. It is possible that no
PCR product was obtained for strain E3T because the DNA extraction process was
unsuccessful, or perhaps resulted from a missing component in the PCR reaction
mixture. Subsequent repeat PCR reactions with this strain yielded a fragment of the
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expect size. Where a second band of approximately twice the size of the desired
product is also visible, this is likely to be a dimer of PCR product due to overloading
of the gel. No bands were observed for the negative controls E. coli NCTC 10418
(lane 6) and P. aeruginosa NCTC 662 (lane 7). Two further negative controls were
included to screen PCR reagents for possible bacterial contamination as follows:
PCR reaction mixture without DNA extract (lane 8); PCR reaction mixture with
DNA extract (strain NCTC 6571) but no primers (lane 9). The grlA PCR products of
all five S. aureus strains were loaded in lanes 11 to 15 in the same order as before.
Bands of the expected size (400 to 500 bases) were observed for all strains. No
bands were observed for any of the negative controls (lanes 16 to 19).
4.2.4 PCR Amplification and Sequencing of the QRDRs of GyrA and GrlA
After establishing that the appropriate size of gene fragments could be amplified with
the chosen PCR primers, the QRDRs of gyrA and grlA for all 16 strains, detailed in
Table 4.4, were amplified and purified as described in section 2.4.11. The QRDR of
each gene was amplified and sequenced twice from two different DNA extracts for
each strain. The approximate DNA content of each purified PCR product was
quantified to between 30 and 90ng/pL and submitted for automatic DNA sequencing.
The nucleotide and amino acid sequences of the QRDR of wild-type S. aureus gyrA
and grlA genes are shown in Figures 4.4 and 4.5. The key mutation hotspots are at
codons 84, 85 and 88 in gyrA and 80 and 84 in grlA, although mutations have also
been found outwith these codons. These codons (shaded in grey in the figures)
encode serine and glutamic acid in a wild-type strain.
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Figure 4.4: QRDR fragment ofwild-type S. aureus gyrA gene
ACAATTTATAGAAGATAATGCAGTTTATGCAAACTTA GAC TTC TAA GCG CTG 2252
QFIEDNAVYANL D F ***
TGA ACT GAA CTT TTG AAG GAG GAA CTC TTG ATG GCT GAA TTA CCT 2297
M A^ E L P
CAA TCA AGA ATA AAT GAA CGA AAT ATT ACC AGT GAA ATG CGT GAA 2342
QSRINERNITSEMRE
TCA TTT TTA GAT TAT GCG ATG AGT GTT ATC GTT GCT CGT GCA TTG 2387
S FLDYAMSVIVARAL
CCA GAT GTT CGT GAC GGT TTA AAA CCA GTA CAT CGT CGT ATA CTA 2432
PDVRDGLKPVHRRIL
TAT GGA TTA AAT GAA CAA GGT ATG ACA CCG GAT AAA TCA TAT AAA 24 77
YGLNEQGMTPDKSYK
AAA TCA GCA CGT ATC GTT GGT GAC GTA ATG GGT AAA TAT CAC CCT 2522
KSARIVGDVMGKYHP
CAT GGT GAC TCA TCT ATT TAT GAA GCA ATG GTA CGT ATG GCT CAA 2567
H G D S S i YE AMVRMAQ
GAT TTC AGT TAT CGT TAT CCG CTT GTT GAT GGC CAA GGT AAC TTT 2612
DFSYRYPLVDGQGNF
GGT TCA ATG GAT GGA GAT GGC GCA GCA GCA ATG 264 6
G S M D G D G A A A M
*** denotes stop codon; underlining indicates primer sequence locations
► indicates beginning ofgyrA gene;
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Figure 4.5: QRDR fragment of wild-type S. aureus grlA gene
GTGAAATAATTCAAGATTTATCACTTGAA GAT GTT TTA GGT GAT CGC TTT 2085
EI IQDLSLE D V L G D R F
GGA AGA TAT AGT AAA TAT ATT ATT CAA GAG CGT GCA TTG CCA GAT 2130
GRYSKYI IQERA^LPD
GTT CGT GAT GGT TTA AAA CCA GTA CAA CGT CGT ATT TTA TAC GCA 2175
VRDGLKPVQRRILYA
ATG TAT TCA AGT GGT AAT ACA CAC GAT AAA AAT TTC CGT AAA AAT 2220
MYSSGNTHDKNFRKN
TTC CGT AAA AGT GCG AAA ACA GTC GGT GAT GTT ATT GGT CAA TAT 2265
FRKSAKTVGDVI GQY
CAT CCA CAT GGA GAC TCC TCA GTG TAC GAA GCA ATG GTC CGT TTA 2310
HPHGDS SVY E AMVRL
AGT CAA GAC TGG AAG TTA CGA CAT GTC TTA ATA GAA ATG CAT GGT 2355
SQDWKLRHVLIEMHG
AAT AAT GGT AGT ATC GAT AAT GAT CCG CCA GCG GCA ATG CGT TAC 2400
NNGS I DNDPPAAMRY
ACT GAA GCT AAG TTA AGC TTA CTA GCT GAA GAG TTA TTA CGT GAT 2445
TEAKLSLLAEELLRD
ATT AAT AAA GAG ACA GTT TCT TTC ATT CCA AAC TAT GAT GAT ACG 2490
INKETVSFIPNYDDT
ACA CTC GAA CCA ATG GTA TTG CCA TCA AGA TTT 2535
TLEPMVLPSRF
*** denotes stop codon;
F indicates beginning ofgrlA gene,
underlining indicates primer sequence locations
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The DNA sequences of NCTC 8325/4 and all 15 mutant strains were compared to
these wild-type sequences. Table 4.5 shows all mutations detected in these strains.
All parent strains are indicated with grey shading. All first-step strains were selected
from strain NCTC 8325/4. Second-step strains ED258 and ED261 were selected
from ED223, while ED268, ED276 and ED277 were selected from ED229. All
third-step strains were selected from ED268.
Table 4.5: Mutations in the QRDRs of gyrA and grlA of moxifloxacin-selected
mutants.
gyrA Mutations grlA Mutations




ED 170 - -
ED209 - -
ED216 - -
ED223 - 80 TCC—>TTC Ser—>Phe
ED229 - -
2nd Step
ED258 84 TCA—>GCA Ser—>Ala 80 TCC—>TTC Ser—>Phe
ED261 84 TCA—>GCA Ser-»Ala 80 TCC—>TTC Ser—>Phe
ED268 84 TCA->TTA Ser—»Leu -
ED276 84 TCA-GTTA Ser—>Leu -
ED277 88 GAA-»AAA Glu—>Lys -
3rd Step
ED357 84 TCA-GTA Ser—»Leu 84 GAA—>AAA Glu->Lys
ED360 84 TCA—»TTA Ser-»Leu 84 GAA-»AAA Glu^Lys
ED375 84 TCA-»TTA Ser->Leu 84 GAA^AAA Glu—>Lys
ED377 84 TCA-VTTA Ser—>Leu 84 GAA—>AAA Glu—»Lys
ED385 84 TCAh-TTA Ser—»Leu 84 GAA->AAA Glu->Lys
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A small decrease in quinolone sensitivity could be detected in first-step mutants by
determination of MICs. However, a comparison of the gyrA QRDR sequences with
parent strain NCTC 8325/4 did not reveal any nucleotide point mutations in mutant
strains (Table 4.5). Strain ED223 had a point mutation at serine 80 altering the
amino acid to phenylalanine, however this did not confer a higher level of resistance
than was observed in the other four strains in which no mutations were detected.
Clearly some other mutation outwith the QRDR, or another mechanism of resistance
is responsible for the decreased quinolone sensitivity in strains ED 170, ED209,
ED216 and ED229.
Second-step mutant strains ED258 and ED261 were derived from first-step mutant
strain ED223, and sequencing analysis revealed that both strains had inherited the
grlA Ser80 to Phe mutation present in the parent strain (Table 4.5). All five second-
step mutants had alterations at either Ser84 or Glu88 in gyrA, although strains
ED268, ED276 and ED277 had no detectable mutation in grlA. All five strains had
an associated large increase in MIC. The double mutation in strains ED258 and
ED261 did not confer higher MICs of moxifloxacin or sparfloxacin on these strains.
However, MICs of ciprofloxacin and trovafloxacin were one dilution higher for these
strains than for ED268, ED276 and ED277. Although three different point mutations
within two different codons (84 and 88) were detected in gyrA, all apparently
conferred the same change in resistance to moxifloxacin.
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All third-step mutant strains had the Ser84 to Leu mutation already detected in the
parent strain ED268. In addition all five strains had the same Glu84 to Lys mutation
in topoisomerase IV. All strains had high level resistance to the quinolones tested.
The single gr/A mutation identified in Table 4.5 was the only difference between
these strains and their more sensitive second-step parent, therefore this mutation (or a
combination of this mutation plus the gyrA mutation) is playing a significant part in
the development from low- to high-level resistance.
4.3 Ciprofloxacin-selected Quinolone ResistantMutants
The sequencing results obtained for mutants selected with moxifloxacin indicate that
DNA gyrase could be the primary target of this quinolone rather than topoisomerase
IV. This result could be due to the specific molecular structure of moxifloxacin that
may allow it to have different interactions with the DNA gyrase-DNA complexes
compared to other agents. In order to investigate the hypothesis that moxifloxacin
and ciprofloxacin have different cellular targets, first- and second-step mutants were
selected with ciprofloxacin by the method previously described for moxifloxacin
(section 2.4.6).
4.3.1 Second-step Ciprofloxacin-selected Mutants
In the first instance, second-step mutants were selected from EDI 70, a first-step
moxifloxacin-selected strain known to have no mutations within gyrA or grlA. This
strain was assumed to have an efflux mutation that would account for the small
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increase in moxifloxacin MIC. A first-step strain was chosen in order to circumvent
any initial mutation occurring outwith the two target genes, and hence select progeny
with a gyrA or grlA mutation in a single mutation step. Mutants selected with
ciprofloxacin were screened in order to identify strains with moxifloxacin and
ciprofloxacin MICs equivalent to, or higher than, those determined for second-step
moxifloxacin-selected strains. Five strains were chosen for DNA sequencing.
Table 4.6 details the MICs and mutations found to be present in these strains.
Table 4,6: Ciprofloxacin-selected second-step mutants
MIC (mg/L) Mutation
Strain Cip Moxi gyrA grlA
ED565 >16 0.25 - -
ED566 4 0.75 TCA-»TTA Ser84—»Leu -
ED567 8 0.25 - -
ED568 16 0.5 TCA—>GCA Ser84-»Ala -
ED569 >16 0.75 _ _
Only two out of the five strains showed any mutation within the QRDRs ofgyrA and
grlA. Interestingly, the strains with the highest MICs of ciprofloxacin had no
detectable mutations. None of these second-step mutants were found to have
mutations in grlA. Strains ED566 and ED568 had a mutation at codon 84 in gyrA,
and this result is the same as was found for moxifloxacin-selected second-step
mutants (Table 4.5).
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4.3.2 First-step Ciprofloxacin-selected Mutants
The second-step ciprofloxacin-selected mutants were progeny of a moxifloxacin-
selected first-step parent strain. It is possible that undetermined effects of
moxifloxacin on this parent strain could have influenced the outcome of mutant
selection to second-step level with ciprofloxacin. To further test the hypothesis that
ciprofloxacin targets topoisomerase TV and that therefore mutations arise in grlA
before gyrA, first-step mutants were selected from the standard parent strain NCTC
8325/4 with ciprofloxacin by the method described previously (section 2.4.6).
Table 4.7: Ciprofloxacin-selected first-step mutants
MIC (mg/L) Mutation
Strain Cip Moxi gyrA grlA
ED571 2 0.25 - -
ED572 2 0.12 - TCC—»TAC Ser80-»Tyr
ED573 2 0.25 - -
ED574 1 0.06 - -
ED575 2 0.12 - -
ED576 1 0.25 - -
ED577 1 0.25 _ _
Seven first-step mutants were selected for DNA sequencing. The results are shown
in Table 4.7. The results were similar to those described previously for moxifloxacin
(Table 4.5). No mutations were detected in gyrA in any of the strains, and although
all strains had increased MICs of ciprofloxacin compared to parent strain NCTC
8325/4 only one strain (ED572) was found to have a mutation within grlA. The
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mutation detected in strain ED572 was at codon 80 and did not elevate the MIC to a
concentration greater than determined for the other six strains with unknown
mutations.
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Chapter 5: Results - Non-gyrA- or -grlA-mediated
Resistance.
Quinolone resistance in S. aureus is not only mediated by changes within the A
subunits ofDNA gyrase and topoisomerase IV, but has also been attributed in part to
mutations within gyrB or gr/B, and enhanced efflux pump expression. However, it is
believed that individually these mechanisms confer only low levels of resistance, and
that they can only contribute to high level resistance in combination with gyrA and
grlA mutations. The small decrease in sensitivity that they confer may be important
in prolonging the survival of the bacterium after the initial quinolone challenge. This
in turn may provide sufficient time to enable the bacterium to develop higher levels
of resistance through gyrA or grlA mutations. Chapter 4 described a series of
step-wise selected quinolone resistant mutants that were investigated for the presence
of mutations in the QRDRs of gyrA or grlA. Several first-step mutants had no
mutations within the QRDRs and were subjected to further investigation.
5. 1 Mutations in GyrB
Of the five first-step moxifloxacin-selected mutants characterised for gyrA or grlA
mutations by DNA sequencing, only ED223 was found to have a grlA mutation. The
decreased quinolone sensitivity observed by sensitivity testing of the other four
strains must therefore be due to a mutation or mutations elsewhere in the genome.
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PCR amplification of the gyrB gene was performed using the cycle parameters and
primers described by Takahashi et al (1998). A 327 base fragment of gyrB was
amplified successfully for the parent strain and all five first-step mutants as shown in
Figure 5.1 (Lanes 4 and 6 to 10 respectively). Lane 1 shows the 100 base pair
ladder; Lane 2 shows E. coli NCTC 10418 as a negative control; Lanes 3 and 5
contain S. aureus NCTC 6571 and strain ED3 respectively as positive controls.
Figure 5.1: Amplified 327 base fragment ofgyrB
The PCR products were purified, quantified and sequenced as previously described
(sections 2.4.11 and 2.4.12). The resulting sequence data was compared to a
wild-type gyrB gene (Margerrison and Hopewell, 1992), but no mutations could be
detected within the amplified region.
5.2 Investigation ofEfflux as a Resistance Mechanism
Enhanced efflux resulting from mutations in a promoter region, resulting in increased
expression of the NorA multi-drug efflux pump of S. aureus, has been described as a
mechanism of resistance to some quinolones. Over expression of this constitutive
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pump may prolong the survival time of the bacterium after exposure to low
concentrations of quinolone.
5.2.1 Sensitivity to Efflux Pump Substrates
A preliminary way of investigating the presence or absence of enhanced efflux pump
expression is to examine the sensitivity profiles of bacteria to efflux pump substrates.
Typical substrates include tetracycline, ethidium bromide and the quinolones, and
MICs of these substrates may be determined by standard methods (British Society
for Antimicrobial Chemotherapy Working Party, 1991). The addition of the plant
alkaloid reserpine, a competitive efflux pump inhibitor, to the sensitivity testing
medium often decreases the MIC of the substrate if a pump is being overexpressed.
The MICs of tetracycline, ethidium bromide and moxifloxacin (with and without
reserpine) are shown in Table 5.1. The MIC of tetracycline was identical for all
strains (0.25mg/L). The addition of reserpine at either 10 or 20mg/L did not have
any effect on the MICs of moxifloxacin. Interestingly, the ethidium bromide MICs
seem to be influenced by the presence of topoisomerase IV mutations. Strains
ED223, ED258, ED261 and all third-step strains had an ethidium bromide MIC of
4mg/L compared to 2mg/L for all other strains, and these strains all had a mutation
within the grlA QRDR. The MICs of moxifloxacin remained the same for all strains
in the presence of lOmg/L or 20mg/L reserpine. Strain ED209 showed a one fold
decrease in sensitivity to moxifloxacin, but this one fold difference is acceptable
within the sensitivity limits of this experiment, and therefore is not significant.
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Table 5.1: Sensitivity moxifloxacin-selected mutants to efflux pump substrates
MICs in mg/L







8325.4 0.25 2 0.06 0.06 0.06
ED 170 0.25 2 0.12 0.12 0.12
ED209 0.25 2 0.12 0.12 0.06
ED216 0.25 2 0.12 0.12 0.12
ED223 0.25 4 0.12 0.12 0.12
ED229 0.25 2 0.12 0.12 0.12
ED258 0.25 4 1 1 1
ED261 0.25 4 1 1 1
ED268 0.25 2 1 1 1
ED276 0.25 2 1 1 1
ED277 0.25 2 1 1 1
ED357 0.25 4 8 8 8
ED360 0.25 4 8 8 8
ED375 0.25 4 8 8 8
ED377 0.25 4 8 8 8
ED385 0.25 4 8 8 8
*Moxifloxacin at the concentrations shown in coiumn 4
5.2.2 Assay for Efflux Activity in the Presence or Absence of CCCP
Several studies have shown the efficacy of efflux assays as an indication of the
overexpression of efflux pumps in both S1. aureus and S. pneumoniae. Efflux can be
measured over time, in the presence or absence of the proton motive force inhibitor
CCCP, by assaying the intracellular accumulation of radiolabeled quinolone.
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Addition of the inhibitor prevents the active efflux process, facilitating build-up of
radiolabeled drug within the cell.
Figure 5.2: Accumulation of radio-labelled moxifloxacin in S. aureus NCTC
8325/4 NCTC 8325/4 -O- NCTC 8325/4+CCCP
Time (minutes)
The accumulation of uC-moxifloxacin in the wild-type parent strain NCTC 8325/4
over a 30 minute period is shown in Figure 5.2. The concentration of detectable
moxifloxacin increases gradually with time. When CCCP was added after 15
minutes, to inhibit the proton motive force and disable any efflux activity, a similar
pattern of accumulation was detected. The patterns of moxifloxacin accumulation in
first-step mutant strains ED 170, ED209, ED216, ED223 and ED229 are shown in
Figures 5.3 to 5.7. All of the accumulation patterns are similar to NCTC 8325/4,
with none of the strains showing significant changes in accumulation with the
addition ofCCCP after 15 minutes.
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Figure 5.4: Accumulation of radio-labelled moxifloxacin in strain ED209
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Figure 5.5: Accumulation of radio-labelled moxifloxacin in strain ED216




















Figure 5.6: Accumulation of radio-labelled moxifloxacin in strain ED223
ED223 —D— ED223+CCCP -^-NCTC 8325/4
Time (minutes)
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Figure 5.7: Accumulation of radio-labelled moxifloxacin in strain ED229
ED229 —O- ED229+CCCP -t^NCTC 8325/4
Time (minutes)
5.2.3 Washing assay
Since no change in efflux was established using the accumulation assay described in
the previous section, a washing assay was employed as an alternative method. The
intracellular concentration of radio-labelled moxifloxacin in each strain was
measured after multiple washing steps. In strains that over-express an efflux pump
such as NorA, export of moxifloxacin from the cells would be expected to be faster
than in strains with wild-type expression ofNorA.
In Figures 5.8 to 5.12 the first-step mutant strains are compared to the wild-type
parent strain NCTC 8325/4.
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Figure 5.8: Efflux of radio-labelled moxifloxacin from strain ED170 compared
to strain NCTC 8325/4
—♦—NCTC 8325/4 -O- EDI 70
Number ofWashes
Figure 5.9: Efflux of radio-labelled moxifloxacin from strain ED209 compared
to strain NCTC 8325/4
-♦-NCTC 8325/4 -O- ED209
Number ofWashes
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Figure 5.10: Efflux of radio-labelled moxifloxacin from strain ED216 compared





Figure 5.11: Efflux of radio-labelled moxifloxacin from strain ED223 compared
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Figure 5.12: Efflux of radio-labelled moxifloxacin from strain ED229 compared
to strain NCTC 8325/4
—♦—NCTC 8325/4 -D-ED229
Number ofWashes
For all strains, the intracellular concentration of moxifloxacin decreases with each
subsequent washing step, and eventually levels out to a minimum. The rate of
quinolone efflux in all five mutant strains is almost identical to the parent strain
NCTC 8325/4. None of the five strains shows significant variation.
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Chapter 6: Results - Murine Subcutaneous Abscess
Model.
One problem with studying the in vitro activity of antimicrobials is relating the
resulting data to the situation in vivo. The artificial conditions used in the laboratory
invariably supply the bacteria with optimal growth conditions in terms of
temperature, nutrients and oxygen. However, these conditions may be restricted in
vivo, resulting in altered growth rate and expression of virulence factors. This, in
turn, will have an impact on the spread and severity of disease. The activity of the
antimicrobial in vivo may be quite different to the activity in vitro, due to interactions
between biological factors (for example immune system components) with both the
infecting bacteria and the antibiotic. Clearly it is therefore important to assess the in
vivo activity as well as the in vitro in the development of any antibiotic, and this may
be achieved through the study of animal models of infection and clinical trials.
6.1 Activity in Murine Subcutaneous Staphylococcal Abscess Model
In this study the activity of moxifloxacin and the development of quinolone
resistance in vivo were investigated in a murine subcutaneous abscess model (Bunce
et al. 1992).
92
Chapter 6: Results - Murine Subcutaneous Abscess Model
6.1.1 In vivo Concentration of Moxifloxacin in Serum and Abscesses
Before the experiment could proceed it was necessary to establish the correct dose of
moxifloxacin to give each mouse in order to achieve specific concentrations within
the abscesses. Mice were infected on the right flank with S. aureus by subcutaneous
injection and left for 48 hours to allow abscesses to develop (Figure 6. la). The mice
were then injected with varying concentrations of moxifloxacin (Figure 6.1b).
Ocular blood samples were taken after 30 minutes and after three hours the animals
were sacrificed and the abscesses excised. The average moxifloxacin concentration
within serum samples and abscesses was established by FfPLC analysis (Table 6.1).
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The levels of moxifloxacin in serum and abscesses could be related back to the
concentration given in the initial injections. With reference to this data, a suitable
dose could be given to achieve the desired multiple of the MIC within abscesses.
6.1.2 In vivo Dose Response Curve
The effect of different doses of moxifloxacin on S. aureus NCTC 8325/4 in
subcutaneous abscesses was investigated. Cohorts of ten mice, infected with wild
type strain S. aureus NCTC 8325/4 (Figure 6.1a), were dosed with sufficient
moxifloxacin to maintain concentrations equivalent to 0, 1, 2 or 4 times the MIC
within the abscesses for 24 hours (Figure 6. lb). Thereafter, the number of viable cfus
could be determined by plating diluted abscess material onto non-selective MHA
plates (Figure 6.1 d). Statistical analyses of the data generated are given in Appendix
IV.







§ 10 -j F
0.00 mg/L 0.05mg/L O.lOmg/L 0.15mg/L
Concentration ofMoxifloxacin in Abscesses
95
Chapter 6: Results - Murine Subcutaneous Abscess Model
The average numbers of surviving cfus per dosing group and 95% confidence limits
are shown in Figure 6.2. There is a clear dose-response effect with the average
number of recoverable cfus decreasing as the given dose ofmoxifloxacin increases.
6.1.3 In vivo Comparison ofMoxifloxacin With Other Quinolones
In order to compare the in vivo effect of moxifloxacin with other quinolones mice
were first infected with S. aureus NCTC 8325/4. Every animal in each cohort of ten
was given 0.12mg/L (2 x MIC) of moxifloxacin, trovafloxacin or grepafloxacin. The
control animals were given phosphate buffered saline only. Statistical analyses of the
number of viable cfus recovered are given in Appendix V.













Figure 6.3 shows that the viable count of cfus. Statistical analysis reveals that the
viable counts recovered from cohorts given quinolone were not statistically lower
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than the control group, although in the previous experiment moxifloxacin at this
concentration (0.12mg/L) reduced the survival almost 100-fold (Figure 6.2).
Although from the figure it appears that more cfus were recovered from the group
treated with grepafloxacin compared to those given moxifloxacin or trovafloxacin,
there was no statistically significant difference between the four groups. In order to
get a better distinction between the different quinolones for further comparison this
experiment was repeated with a starting dose at 0.25 mg/L. Statistical analyses of
the number of cfus recovered are given in Appendix VI. Figure 6.4 shows the mean
survival of cfus as shaded bars.
Figure 6.4: Comparison of three quinolones at 0.25 mg/L
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Although from Figure 6.4 it appears that the numbers of surviving cfus varies
between different dosing cohorts, analysis indicates that there are no statistically
significant differences between these dosing groups.
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6.2 Development of In Vivo Resistance in theMouse Abscess Model
It is difficult to predict how a new antibiotic is likely to select antibiotic resistance in
vivo by merely looking at in vitro data. However, it is important to know whether a
new agent is likely to facilitate rapid selection or spread of resistant strains before it
comes into widespread clinical use. A simple model such as the murine
subcutaneous staphylococcal abscess model, provides an opportunity to study the in
vivo development of resistance in response to antibiotic challenge. The propensity of
moxifloxacin to select for or promote the development of quinolone resistance in this
model was investigated as follows.
6.2.1 First-step Mutants Selected In vivo
Mice were infected with S. aureus NCTC 8325/4 by subcutaneous injection and
treated with moxifloxacin as described previously (section 6.1.2). Mutant selection
from abscess material was performed on selective plates containing moxifloxacin at
1, 2 or 4 times MIC in parallel to determining viable counts of surviving cfus
(Figure 6. lc). Mutants with MICs of moxifloxacin of between 0.1 and 0.14 mg/L
were selected. Table 6.2 details the number of mutants selected and the mutation
frequencies from mice given doses equivalent to 0, 1, 2 or 4 times MIC of strain
NCTC 8325/4.
From the table it can be seen that fewer moxifloxacin-resistant mutants could be
selected from animals treated with moxifloxacin than from the control group, and
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that the mutation frequencies did not significantly change as the dose of
moxifloxacin increased.
Table 6.2: Mean counts and mutation frequencies of first-step moxifloxacin-
resistant mutants selected in vivo
Dose (mg/L) Mean Count Frequency of Mutation
Control (0.00) 90.0 1.7 .x 105
lx MIC (0.06) 3.0 1.6 xlO"5
2 x MIC (0.12) 0.4 4.5 xlO"6
4 x MIC (0.25) 1.1 1.7 xlO"5
The QRDRs of gyrA and grlA of five randomly selected mutants (ED405, ED412,
ED427, ED460 and ED439) were characterised by PCR amplification and DNA
sequencing. All five strains had MICs of moxifloxacin of 0.13 mg/L, however no
mutations were detected within the sequenced regions of gyrA and grlA for any of
these first-step mutants. The mutant selection and sequencing results from these
first-step mutants were in agreement with previous observations for in vitro mutants
(see Chapter 4).
6.2.2 Second-step Mutants Selected In vivo
Strain ED427 was selected as the parent strain for a subsequent mutation step to
select second-step mutants in vivo. Abscesses were induced in mice using strain
ED427, and mice were treated with moxifloxacin at concentrations of 0, 2, 4 or 8
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times the MIC. Although viable cfus could be recovered from abscesses of both
treated and untreated animals, no mutants with elevated MICs could be recovered on
selective plates at 2, 4 or 8 times the MIC of ED427.
In order to eliminate the possibility that there was a problem with strain ED427, the
second-step mutation experiment was repeated with strain ED 170, a well
characterised first-step mutant strain previously selected in vitro. In addition, a
double inoculum was used to increase the number of infecting bacteria and thus
compensate for slower growth of the mutant strain and any possible decrease in
mutation frequency. Mice were treated with an MIC equivalent dose of
moxifloxacin (0.12mg/L). Table 6.3 details the total number of strains recovered on
selective plates (at 1, 2, 3 and 4 times the MIC) from each dosing group and the
mutation frequencies.
Table 6.3: Number of cfus and mutation frequencies of second-step
moxifloxacin-resistant mutants selected in vivo
Dose (mg/L) Total cfu Count Mutation Frequency
Control (0.00) 45 5 x 10"6
MIC (0.12) 62 6x 10"6
The mutation frequencies are similar to those determined for first generation mutant
selection. MICs were determined for all 107 strains recovered on selective plates,
but only one strain (ED570) demonstrated an increase in resistance with an elevated
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MIC of l.Omg/L. The QRDRs of gyrA and grlA in this strain were characterised by
PCR and DNA sequencing. No mutation was detected within the GrlA protein of
topoisomerase IV, however a serine 84 to leucine (TCA to TTA) mutation was found
in gyrA.
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Chapter 7: Results - Mechanisms of Action Against
Characterised Quinolone-Resistant Mutants
In Chapter 3 the in vitro efficacy and mechanisms of action of moxifloxacin against
standard laboratory strains and clinical isolates of S. aureus was investigated by
time-kill kinetics. Many quinolones have been evaluated by this method, but few
studies have also investigated bactericidal activity against characterised quinolone-
resistant mutants. During this project a series of step-wise selected mutant strains
with resistance to moxifloxacin and other quinolones were characterised for
mutations within the QRDRs of gyrA and gr/A. These strains provided a unique
opportunity to investigate the effect of specific mutations and combinations of
mutations on the bactericidal activity ofmoxifloxacin.
7. / Activity ofMoxifloxacin Against CharacterisedMutants
The minimum concentration of moxifloxacin with the maximum killing activity was
established to be l.Omg/L against standard laboratory strains of S. aureus (see
section 3.2). This concentration was used to challenge cultures of quinolone-
resistant S. aureus strains as described previously (section 2.4.5). The number of
surviving cfus at 30 minute intervals were determined by viable count.
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7.1.1 Activity at l.Omg/L Against First-step Mutants
Two first-step mutants with MICs of moxifloxacin of 0.12mg/L were challenged
with moxifloxacin at 1 .Omg/L under three different growth conditions. Strain ED223
had a serine 80 to phenylalanine mutation in the QRDR of grlA, but strain ED229
had no mutations in the QRDRs of gyrA or grlA. Figures 7.1 and 7.2 show the time
kill curves determined for strains ED223 and ED229.
Moxifloxacin showed good bactericidal activity against strain ED223 at 1.Omg/L in
broth, with less than 1% survival after 120 minutes. At the end of the experiment
(210 minutes) only 15% of cfus survived when chloramphenicol was present. Thus
the addition of a bacteriostatic concentration of chloramphenicol did not completely
remove the killing activity of moxifloxacin. Similarly, challenging the strain in PBS
rather than nutrient broth to inhibit cell division did not completely remove killing
activity, as only 40% survival was observed after 210 minutes.
A similar pattern of killing was observed for strain ED229 when challenged with
1.Omg/L ofmoxifloxacin (Figure 7.2). Less than 1% survival was observed in broth
after 90 minutes. Some killing activity was retained in the presence of a
bacteriostatic concentration of chloramphenicol, with only 32% survival of cfus after
210 minutes. Less than 10% survival was observed when strain ED229 was
challenged with moxifloxacin in PBS rather than broth. Figures 7.1 and 7.2 are
almost identical to those observed for the wild-type parent strain NCTC 8325/4
(Figure 3.3).
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Figure 7.1: Activity of moxifloxacin at l.Omg/L against strain ED223 in NB, PBS
or NB with 20mg/L chloramphenicol
• NB ♦ PBS —NB+Chloramphenicol
Time (minutes)
Figure 7.2: Activity of moxifloxacin at l.Omg/L against strain ED229 in NB, PBS
or NB with 20mg/L chloramphenicol
• NB ♦ PBS -•—NB+Chloramphenicol
Time (minutes)
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7.1.2 Activity at l.Omg/L Against Second-step Mutants
The second-step mutants ED258 and ED268 were investigated. The MIC of
moxifloxacin for both strains was 0.8mg/L, which was close to the concentration
used to challenge them (l.Omg/L). Strain ED258 had a double mutation, with a
change at serine 84 to alanine in gyrA in addition to the serine 80 to phenylalanine
mutation in grlA inherited from the parent strain ED223. Strain ED268 had a single
mutation at position 84 in gyrA with an amino acid change from serine to leucine.
Figures 7.3 and 7.4 show the viable counts of surviving cfus for these strains.
Strain ED258 was not killed rapidly, however some killing activity was observed and
after 210 minutes only approximately 32% of cfus were recovered (Figure 7.3). The
number of surviving cfus remained static in PBS, with counts overall constant at
approximately 100%. The presence of chloramphenicol to inhibit protein synthesis
had more effect on the kill rate, with the number of surviving cfus decreasing to
between 40 and 75%. At 210 minutes there was only 30% survival in the presence of
chloramphenicol.
Moxifloxacin was not bactericidal at l.Omg/L against strain ED268 in broth and
more than 180% survival was recorded at 210 minutes (Figure 7.4). However, in
PBS some killing was observed and survival decreased to 67% over 210 minutes.
Moxifloxacin had a greater killing effect in the presence of chloramphenicol with
only 3% survival recorded at 210 minutes.
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Figure 7.3: Activity of moxifloxacin at l.Omg/L against strain ED258 in NB, PBS
or NB with 20mg/L chloramphenicol
NB ♦ PBS —■—NB+Chloramphenicol
Time (minutes)
Figure 7.4: Activity of moxifloxacin at l.Omg/L against strain ED268 in NB, PBS
or NB with 20mg/L chloramphenicol
NB ♦ PBS -B-NB+Chloramphenicol
Time (minutes)
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7.1.3 Activity at l.Omg/L Against a Third-step Mutant
Third-step mutant strain ED360 had a mutational change from glutamic acid to
lysine at position 84 in grlA, and an additional change of serine 84 to leucine in gyrA.
The MIC of this strain (4.5mg/L) was higher than the OBC with which it was
challenged.
Figure 7.5: Activity of moxifloxacin at l.Omg/L against strain ED360 in NB, PBS
or NB with 20mg/L chloramphenicol
t NB ♦ PBS —■—NB+Chloramphenicol
Time (minutes)
From Figure 7.5 it is clear that the OBC has no killing effect on this strain, and after
210 minutes survival was greater than 1600%. Limiting active cell division by
incubation in PBS rather than broth prevented cell multiplication - viable counts
remained at approximately 100% throughout the experiment - but no bactericidal
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activity of moxifloxacin was observed. In the presence of chloramphenicol minimal
killing was observed after 150 minutes, with 75% survival at 210 minutes.
7.1.4 Activity at lOmg/L of Moxifloxacin Against Selected Strains
The OBC of moxifloxacin, as established against sensitive standard strains is
l.Omg/L. This concentration is considerably higher than the corresponding MICs for
these strains. However, although this concentration is greater than the MIC of the
first-step mutant strains, it is close to the MIC of the second-step mutants and lower
than the MIC of the highly resistant third-step strains. Since a challenge with
l.Omg/L of moxifloxacin would not be bactericidal against all of these mutant
strains, one strain from each mutation step was subsequently challenged with
1 Omg/L in broth, PBS or broth including chloramphenicol.
Figure 7.6 shows the time-kill curves for first-step mutant strain ED229 after
challenge with 1 Omg/L of moxifloxacin. As expected, the killing activity of 1 Omg/L
moxifloxacin in broth was rapid with less than 0.01% survival after 210 minutes.
Moxifloxacin had a greater killing effect against bacteria in PBS and in broth
containing chloramphenicol than at l.Omg/L (Figure 7.2), with less than 1% survival
of cfus after 180 and 120 minutes respectively.
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Figure 7.6: Activity of moxifloxacin at lOmg/L against strain ED229 in NB, PBS
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Figure 7.7: Activity of moxifloxacin at lOmg/L against strain ED268 in NB, PBS
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Moxifloxacin was not bactericidal against strain ED268 at a concentration of lmg/L
(Figure 7.4), however the time-kill curve in Figure 7.7 shows that at lOmg/L in broth
there was rapid bactericidal activity. Bacterial survival after 210 minutes in the
presence of chloramphenicol was similar to that determined at l.Omg/L (Figure 7.4).
Flowever, survival in PBS at lOmg/L was reduced with approximately 18% survival
after 210 minutes compared to 67% when challenged with lmg/L.
Figure 7.8: Activity of moxifloxacin at lOmg/L against strain ED360 in NB, PBS
or NB with 20mg/L chloramphenicol
t NB ♦ PBS -NB+Chloramphenicol
Time (minutes)
Figure 7.8 shows the survival of the third-step mutant strain ED360 after challenge
with lOmg/L of moxifloxacin. Increasing the concentration of moxifloxacin from
lmg/L to lOmg/L restored bactericidal activity against this strain, with less than
0.1% survival after 210 minutes in broth. Bactericidal activity was also restored
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against bacteria in PBS or in broth containing chloramphenicol, with 10% and less




As the incidence of infections due to multi-drug-resistant pathogens has continued to
increase, the need for new antibiotics with which to treat such infections has become
more urgent. During the 1990s, several new generation quinolones with a broader
spectrum of activity encompassing Gram-positive as well as Gram-negative
organisms have been developed. Unfortunately, some of these agents have already
been withdrawn, or restricted in their clinical use, due to excessive toxic side effects
(Nightingale, 1999). Moxifloxacin is a new 8-methoxyquinolone with good in vitro
efficacy against both Gram-positive and Gram-negative organisms (Alcala et al.
1999; Balfour and Wiseman, 1999; Al-Nawas and Shah, 1998; Klugman and Capper,
1997; Aldridge and Ashcrafit, 1996; Dalhoff et al. 1996; Kitzis et al. 1996; Wise et
al. 1996), and clinical trials indicate that adverse effects are infrequent (von Keutz
and Schliiter, 1999; Man et al. 1999; Sullivan et al. 1999; Siefert et al. 1999a; Stass
et al. 1998; Kubitza et al. 1996).
Prior to the development of modern molecular biology techniques, the activity of
quinolones was often evaluated through study of time-kill kinetics and mechanisms
of action (Smith, 1984). In the first instance a dose response curve may be
constructed by challenging bacteria in liquid culture with increasing concentrations
of quinolone. Traditionally, the dose response curve of killing by quinolones is
easily recognised by its characteristic biphasic shape. The survival of bacteria
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decreases with increasing concentration of quinolone to a minimum point, the OBC.
Survival subsequently improves with further increases in quinolone concentration
and this has been suggested to be caused by quinolone inhibition of protein synthesis
required for the killing action (Smith, 1984). The results presented in this thesis
show that moxifloxacin did not demonstrate the classic dose response curve observed
for older quinolones in that survival decreased to a minimum point but did not
subsequently increase again. This minimum point was approximately l.Omg/L.
Pirapatrungsuriya (1998) observed a similar non-biphasic pattern of killing when
challenging S. aureus with ciprofloxacin. Although no multiplication was seen at
concentrations greater than l.Omg/L, moxifloxacin was clearly bacteriostatic rather
than bactericidal as some cfus were recoverable. It is possible that bacteria that
survived at high concentrations may have developed a mutation, such as enhanced
efflux, conferring sufficient resistance to allow survival. However, since efflux
mutations have only been correlated to low levels of quinolone resistance (Kaatz and
Seo, 1995; Kaatz et al. 1993) it seems unlikely that this mechanism would account
for survival against high moxifloxacin concentrations. It is also possible that the
duration of this experiment was insufficient to allow an increase in the bacterial
population, and that given longer incubation times the number of surviving cells
could eventually begin to increase as resistant strains multiply. Quinolones are
known to inhibit cell division and septation, causing cell filamentation. This process
is associated with disruption in topoisomerase IV function although the underlying
mechanisms have not been fully determined (Maxwell and Critchlow, 1998). The
bacteria surviving after exposure to high quinolone concentrations may therefore
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have been strains that survived by becoming filamentous, enabling cell survival but
not multiplication. New quinolones such as moxifloxacin may have different
molecular targets compared to older agents, and this may account for variation in the
classic biphasic response curve. Interestingly, moxifloxacin does exhibit a classic
biphasic dose response against the Gram-negative bacterium Acinetobacter
banmannii (Higgins et al. 1999).
Survival of quinolone sensitive strains (both laboratory standards and clinical strains)
was reduced to less than 1% by 210 minutes when challenged with l.Omg/L.
Although resistant strains ED3 and ED5 survived after challenge with l.Omg/L, less
than 1% survived after challenge with 4.0mg/L, a concentration equivalent to two
times the MIC for these strains. Pharmacokinetic data for moxifloxacin indicate that
serum concentrations of 4.73mg/L are achievable in vivo, so treatment of infection
with resistant strains such as these should not present a therapeutic problem (Stass et
al. 1998).
At least four bactericidal mechanisms, termed A, B, B' and C, have been described
for the quinolones (Smith and Zeiler, 1998). However, not all mechanisms are
exhibited by all quinolones, and some quinolones demonstrate different killing
mechanisms against different organisms (Lewin and Smith, 1988). Quinolone killing
by mechanism A, found for all quinolones, requires active protein synthesis and cell
division and is observed when challenging a strain in broth. Although the molecular
basis of mechanism A has not been fully elucidated, it has been suggested that it is
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related to the blocking of replication by the formation of cleavable complexes
between a quinolone and DNA gyrase on DNA strands (Chen et al. 1996).
Moxifloxacin was able to kill by mechanism A in all cases. The growth of strains
ED3 and ED5 was not inhibited by subinhibitory concentrations of moxifloxacin
(l.Omg/L), but increasing the moxifloxacin concentration restored bactericidal
activity. It is clear that moxifloxacin is still able to kill these strains by mechanism A
albeit at higher concentrations.
Mechanisms B, B' and C, do not require both protein synthesis and cell division and
can be observed when either or both are inhibited. The data in this thesis show that
killing by moxifloxacin is observed irrespective of the presence of protein synthesis
or cell division against strains NCTC 6571, NCTC 8325/4 and E3T. These data
indicate killing by another mechanism is present in addition to mechanism A. This is
confirmed in the case of clinical strains ED7 and ED9 which show similar patterns of
killing kinetics. To date mechanisms B' and C have only been observed in Gram-
negative organisms with older agents (Lewin and Amyes, 1990; Lewin et al. 1989;
Ratcliffe and Smith, 1985). Mechanism B acts independently of RNA or protein
synthesis and may be related to dissociation of the DNA gyrase subunits. This
mechanism has been described for several quinolones including new agents similar
to moxifloxacin such as sparfloxacin (Lewin et al. 1992). Mechanism C has been
suggested to relate to the trapping of cleavable complexes between a quinolone and
topoisomerase IV (Maxwell and Critchlow, 1998). Since moxifloxacin targets
topoisomerase IV as well as DNA gyrase in S. aureus this mechanism of action may
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be present. In this thesis, mechanisms of action in addition to mechanism A were
investigated only by the addition of a bacteriostatic concentration of chloramphenicol
to the test strain (or incubation in PBS) at the same time that moxifloxacin was
added. However, while this shows the presence of an additional mechanism of
action, studies with inhibitor combinations instead of a single agent are necessary to
conclusively differentiate between mechanisms B, B' and C. Studies by
Pirapatrungsuriya (1998) showed that time-kill studies may not always be an
accurate method of identifying the presence of mechanism B, since for E. coli the
effect of the inhibitors chloramphenicol and rifampicin vary greatly, depending
whether they are added before, together with or after the quinolone. Therefore,
although moxifloxacin exhibits a second mechanism of action in addition to
mechanism A, it is not possible to conclude whether this mechanism is B, B' or C
from the data given in this thesis. Indeed the same is likely to be true for all studies
that have reported these mechanisms but have not altered the timings of the protein
and RNA synthesis inhibitors.
The activity and mechanisms of quinolone action against characterised
quinolone-resistant mutants have rarely been investigated although a significant
amount of work has been published about standard sensitive strains. Mutations
within DNA gyrase or topoisomerase IV may effect the degree of DNA supercoiling
and hence the rates of transcription (Bagel et al. 1999). This, in turn, will have an
impact on protein expression and hence growth rate or doubling times, which may be
detectable by time-kill experiments. A specific mutation that extends the survival of
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a bacterium longer than other mutations, i.e. long enough for subsequent changes to
occur leading to higher levels of resistance, will give a selective advantage. If this
occurs in vivo, strains with specific mutations will tend to dominate. In Chapter 7 the
results of a study to investigate the effect of specific mutations in gyrA and grlA on
the time-kill kinetics of moxifloxacin are given. As expected, moxifloxacin was
rapidly bactericidal at l.Omg/L against first-step mutant strains ED223 and ED229,
for which this concentration was much greater than the MIC. However, only the
second-step strain ED258 was killed at l.Omg/L, with strain ED268 surviving and
multiplying, and third-step strain ED360 was not killed at l.Omg/L. It is not clear
why strain ED258 (with both a gyrA and a grlA mutation) should be killed more
efficiently than strain ED268 (which had only a gyrA mutation). However, it may be
that an efflux mutation, which ED268 may have acquired at the primary mutation
step, confers an advantage over the grlA80 mutation of ED258 by decreasing the
intracellular concentration of quinolone. This could reduce the degree of
quinolone-induced DNA cleavage and allow the SOS system to repair the damage
and prolong survival. Since prolonged survival increases the chance of a new
mutational event occurring, which will confer greater quinolone resistance, it would
be interesting to isolate and sequence strains from the end point of this experiment to
determine whether additional mutations have arisen. When strains ED229, ED268
and ED360 were subsequently challenged with a 10-fold higher concentration of
moxifloxacin, killing activity was restored against highly resistant strains with
survival of all strains decreasing to less than 0.1% after 210 minutes. Tn all cases
killing was rapid and, given the relatively short time frame of these experiments,
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there were no significant differences between the survival times of different strains.
Increasing the duration of quinolone challenge would give a better idea of the ability
of strains to recover from challenge and the propensity for long term survival, and
has been done in some studies (Thomson and Sanders, 1998).
From these results there is no evidence to suggest that the specific mutations in these
strains affect the growth rate in vitro, or that certain strains will survive longer than
others after quinolone challenge. However, it is unclear how these data may relate to
survival in the clinical situation, as the effect of these mutations on the in vivo
pathogenicity of these strains is unknown. One recent study of the activity of a
variety of experimental quinolones compared to ciprofloxacin, against sensitive and
resistant strains of S. aureus, found that those with a C-8-methoxy group were
particularly effective against first-step mutants carrying only a gr/A mutation (Zhao
et al. 1998). Clearly a quinolone, which is better able to eradicate first-step mutants,
could have significant benefits in preventing the development of high-level
resistance if used appropriately in the clinical situation. This study also found the
presence of a C-8-methoxy group conferred better activity against non-growing cells
than that observed for quinolones lacking this group. A reduction in the number of
viable static-phase cells also minimises the possibility of a mutation occurring (Zhao
et al. 1998). In addition to this, Dong et al (1999) investigated the relationship
between quinolone structure and resistance by assessing the effect of concentration
on the recovery ofmutants. By applying 1010 cells to agar plates containing various
concentrations of quinolones, they determined a concentration above the MIC at
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which no mutants could be recovered. This concentration was termed the mutant
prevention concentration (MPC), and seems to be lowered by the presence of a
C-8-methoxy group. The potential advantage of determining the MPC is illustrated
in Figure 8.1. In the clinical situation, concentrations represented by the shaded area
should be avoided: concentrations below the MIC do not prevent cell growth and
promote the selection ofmutants; concentrations between the MIC and the MPC also
allow growth of resistant mutants; concentrations above the maximum safe
concentration are toxic to the patient. Establishing the MPC may be a useful method
of determining agents least likely to select resistance (Dong et al. 1999).
Figure 8.1: Diagram representing the MPC
Serum or Tissue
Concentration
Resistance to the quinolones in S. aureus is known to develop in a step-wise manner
through sequential mutations in the genes encoding DNA gyrase, topoisomerase IV
or efflux pumps. Ferrero et al (1995; 1994) showed that topoisomerase IV is a
quinolone target in S. aureus when mutants are selected in a step-wise manner. With
ciprofloxacin as the selective agent, grlA mutations were selected before gyrA
mutations, leading to the assumption that topoisomerase IV is the primary target of
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quinolones in S. aureus. However, ciprofloxacin primarily targets Gram-negative
organisms unlike moxifloxacin that also has good anti-Gram-positive activity,
therefore the targets of moxifloxacin could be different from ciprofloxacin. In this
study the step-wise development of resistance to moxifloxacin was investigated to
establish the progression of mutations and the primary molecular target in S. aureus.
Sensitivity testing confirmed that there was cross-resistance between different
quinolones although strains with identical MICs of moxifloxacin did not always have
identical MICs for all other quinolones tested. However, for some quinolones the
pattern of sensitivity correlated with the presence of mutations in gyrA and
grlA: second-step strains ED258 and ED261 had two mutations (gyrA and grlA), and
both showed higher MICs of ciprofloxacin and trovafloxacin than the other
second-step mutants. Mutations in gyrA were selected before mutations in gr/A in
the majority of strains. Thus it is valid to suggest from these data that DNA gyrase is
the primary target of moxifloxacin, rather than topoisomerase IV, because it is the
primary site of resistance mutations.
Ferrero et al (1995) proposed topoisomerase IV as the primary target of
ciprofloxacin in S. aureus, because grlA mutations always preceded gyrA mutations.
However, in this thesis strains selected with ciprofloxacin showed the same pattern
of mutation as those selected with moxifloxacin, with mutations found in DNA
gyrase and not in topoisomerase IV in the majority of strains. Ferrero et al (1995)
concluded that mutations in grlA must be a prerequisite to mutations in gyrA,
however the results of this thesis clearly show that this is not necessarily true.
120























































*Indicatesundeterminedm tationsth tarow hiQRDRs.Theseybeffluxi .
Chapter 8: Discussion
Sulavik and Barg (1998) stated that a gyrA mutation without an accompanying grlA
mutation can have no effect on quinolone susceptibility and reasoned that this was
why no such mutations have been identified amongst first-step in vitro mutants.
Although gyrA mutations have not been identified in first-step in vitro mutants, it is
clear from this thesis that gyrA mutations can have a significant impact on strain
sensitivity in the absence of grlA mutations. From these data, DNA gyrase appears
to be the primary target of both moxifloxacin and ciprofloxacin in S. aureus.
Table 8.1 gives a summary of the results of several key mutation studies. In vitro
studies of S. pneumoniae have indicated that newer quinolones such as sparfloxacin
and clinafloxacin have DNA gyrase and topoisomerase IV as dual targets (Varon et
al. 1999; Pan and Fisher, 1998; Pan and Fisher, 1997). In another recent study the
primary quinolone target in Mycoplasma hominis was found to vary depending on
the selective agent - sparfloxacin selected gyrase mutations but ofloxacin selected
topoisomerase IV mutations from the same parent strain (Kenny et al. 1999).
Evidently these studies and the evidence of this thesis disprove the theory that all
quinolones primarily target DNA gyrase in Gram-negative organisms and
topoisomerase IV in Gram-positive organisms.
The fundamental question, however, is whether these results generated in vitro with
laboratory strains accurately reflect the progression of resistance in clinical strains.
Clearly it is difficult to assess the step-wise development of high-level resistance in
vivo, as many clinical strains carry multiple mutations. Clinical studies generally
show that the majority of strains with high-level resistance have at least one mutation
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in gyrA and one in grlA, and often multiple mutations in both genes (MunozBellido
et al. 1999; Schmitz et al. 1998; Takahashi et al. 1998; Wang et al. 1998; Deplano
et al. 1997). Schmitz et al (1998) found one strain out of 116 isolates with a gyrA
mutation alone, and this reflects the rarity of these mutants. However, single grlA
mutations are commonly found and this has been taken as confirmation of the
hypothesis of topoisomerase IV as the primary quinolone target that mutates first in
S. aureus. However, in the study of Schmitz et al (1998) only two out of 116 strains
had grlA mutations alone, showing them to be as rare as single mutations in gyrA.
Although single grlA mutations appear to be more frequently isolated than gyrA
mutations in clinical Gram-positive isolates, this may be because single gyrA
mutations are very unstable in vivo, and therefore are rarely detected. This
hypothesis has yet to be investigated. At present the evidence from clinical studies
appears to be in favour of in vitro findings regarding topoisomerase IV as the
primary target; however the number of available studies remains few and there are
great risks in drawing firm conclusions from limited data. Although one
retrospective resistance progression study in clinical E. coli has been described (Gill
et al. 1999), tracing the development of resistance from quinolone-sensitive to
quinolone-resistant in a series of clinical isolates is rarely possible. Employing an
accurate animal model of Gram-positive infection that utilises clinically relevant
pathogenic strains and therapeutic regimens may be a possible way to investigate the
relationship between in vitro and in vivo data further.
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How the role of efflux mutations fits into the process of the development of
quinolone resistance is also not well understood. Ferrero et al (1995) suggested that
efflux mutations, as well as gyrA mutations, are secondary events occurring after
mutations in grlA, based on an in vitro model of resistance development. However,
an in vivo study of the development of low-level quinolone resistance in S. aureus
has indicated altered efflux may in fact be a primary mutational event, and an
alternative to the development of topoisomerase IV mutations (Sulavik and Barg,
1998). In this study low-level quinolone resistance was observed in five first-step
S. aureus mutants. Four of these strains (ED170, ED209, ED216 and ED229) had no
mutations within the QRDRs of gyrA and grlA. In order to account for the increase
in MIC in these strains, overexpression of an efflux pump and gyrB mutations were
investigated as possible mechanisms of resistance. Sensitivity testing was carried out
with tetracycline and ethidium bromide, both of which are efflux pump substrates.
Only ED223 showed an elevated MIC of ethidium bromide, while all other strains
had identical MICs to the parent strain NCTC 8325/4. Enhanced expression of an
efflux system may be observed if the plant alkaloid reserpine is incorporated into a
standard sensitivity test (Brenwald et al. 1997). Reserpine competitively inhibits
efflux of the quinolone rendering the organism sensitive to quinolone concentrations
lower than the MIC - effectively the MIC is reduced. However, in this study only
strain ED209 showed a lowered MIC in the presence of 20mg/L of reserpine. This
suggests that these strains may not be resistant to moxifloxacin by virtue of an
enhanced efflux system. Enhanced efflux was investigated more fully by assaying
both quinolone accumulation and quinolone efflux from the bacterial cells. In the
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first instance the accumulation of radio-labelled moxifloxacin was not found to be
influenced by subsequent addition of CCCP. This agent is a proton motive force
inhibitor that should prevent efflux by the NorA protein, leading to greater
intracellular accumulation of quinolone (Kaatz et al. 1993). In a wild-type strain
with normal low-level expression ofnorA efflux pumps (and hence high intracellular
quinolone concentrations), the change afforded by the addition of CCCP may be
slight. However, the difference between intracellular quinolone concentrations pre-
and post-inhibition should be greater if a strain is over-expressing an active efflux
pump. In these experiments the addition of CCCP did not have any appreciable
effect on the rate of intracellular quinolone accumulation in any of the strains. No
difference could be distinguished between the wild-type strain NCTC 8325/4 and the
first-step mutants. A washing assay was then employed as a more direct
measurement of efflux instead of accumulation. The rate of efflux of radio-labelled
moxifloxacin was found to be the same for all strains, and no significant difference in
rate was observed when each mutant strain was compared to the parent strain NCTC
8325/4, which has wild-type efflux pump expression. These efflux results confirm
those previously obtained by accumulation assays and MICs with reserpine.
Although norfloxacin has often been used to study efflux of quinolones, the new
generation quinolones are poor efflux pump substrates (MunozBellido et al. 1999).
Other studies have also shown moxifloxacin to be a poor substrate, largely
unaffected by the NorA efflux pump (Piddock and Jin, 1999a; Piddock et al. 1999b).
However, it was valid to investigate efflux with moxifloxacin instead of norfloxacin
125
Chapter 8: Discussion
in order to explain the small increases in moxifloxacin resistance in first-step
mutants.
From these experiments there was no evidence to suggest that the low-level
resistance observed in the first-step mutant strains is due to enhanced efflux by
NorA. Another mechanism must therefore have been responsible for resistance in
these first-step strains, and mutations in gyrB or grlB were thought to be relevant.
DNA sequencing data revealed that all first-step mutants had identical gyrB
sequences to the parent strain NCTC 8325/4, excluding mutations in this region from
contributing to low level resistance in these strains. However, only a small fragment
of the gene was investigated so it is possible that mutations outwith the 327 base
region investigated may be present in these strains. Although grlB mutations have
often been looked for in quinolone resistant clinical isolates of S. aureus (Takahashi
et al. 1998), they have only rarely been found. Such mutations are thought to have a
role in the progression to resistance (Tanaka et al. 1998), but their precise
contribution is unclear as they have always been found in combination with
mutations in gyrA or grlA. The novel nature of these mutations suggests that they
may be of lesser importance to the bacterium in terms of enhancing resistance. The
results of this thesis suggest that DNA gyrase should be considered as the primary
target of moxifloxacin. If this is the case, then mutations within gyrB are likely to
arise before mutations in grlB\ however no mutations in gyrB were detected.
Therefore grlB mutations were considered unlikely to be present and were not
investigated. Although efflux mutations were not confirmed as a mechanism of
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resistance in any of the strains in this study, the pattern of mutation development
seems to correlate with the findings of Sulavik and Barg (1998). Figure 8.2 gives a
diagrammatic representation of the development of resistance from sensitive to
highly resistant strains when selected with moxifloxacin. In Figure 8.2(a) it can be
seen that the primary mutation may either be in grlA of topoisomerase IV (ED223),
or in some as yet undetermined locus, possibly leading to altered efflux (ED229).
Both pathways confer the same level of resistance to moxifloxacin. Subsequently,
second-step mutations occur in gyrA in both pathways (Figure 8.2(b)). Thereafter, a
third-step mutation occurs in gr/A (Figure 8.2(c)). It seems likely that the third
mutation following the left fork of the diagram would be an additional grlA mutation.











The data in this thesis point to DNA gyrase as the primary target for both
moxifloxacm and ciprofloxacin in mutants of strain NCTC 8325/4, however
mutation studies can only point to targets not prove them. Therefore, in order to
confirm the targets of moxifloxacin it will be essential to investigate the effects of
individual mutations by site-directed mutagenesis. At least one study has already
shown this to be a useful method for evaluating the interaction between the asp87
residue ofgyrA and quinolones in E. coli (Yonezawa et al. 1995). Enzyme assays to
establish catenation or decatenation, supercoiling, and binding activities of both wild
type and mutant DNA gyrase and topoisomerase IV proteins in the presence of
quinolones have also been implemented (Gootz et al. 1999; Schedletzky et al. 1999;
Maxwell and Critchlow, 1998; Tanaka et al. 1997; Critchlow and Maxwell, 1996;
Tanaka et al. 1995; Willmott and Maxwell, 1993). However, it is not clear how well
inhibitory concentrations of quinolone determined by enzyme inhibition assays
correlate with those obtained through standard MIC testing, as little enzyme
inhibition is required to inhibit cell growth, while 90% inactivation is required to
prevent enzyme activity (Schedletzky et al. 1999). Also, since these studies are
based on extracellular assays of purified enzymes, it is not clear if the results can be
directly related to the clinical situation.
Since the clinical progression of a strain from a sensitive to a resistant phenotype
may be completely different to the in vitro progression, the effect of therapeutic
doses of moxifloxacin on S. aureus strains in subcutaneous abscesses in mice was
determined. This simple model of infection is perhaps more relevant to human
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infection than peritonitis, mastitis or renal abscess models, since S. aureus is the
leading cause of nosocomial wound infections and is less commonly implicated in
these other infections (Bunce el al. 1992). Some qumolones, for example ofloxacin
and sparfloxacin, have been shown to have a concentration-independent killing effect
in vivo (Dalhoff, 1999). In the first instance it was established that moxifloxacin was
able to kill S. aureus in a dose-dependent manner. This result might seem
predictable from in vitro results but these results often do not correlate with the in
vivo situation. It was not possible to distinguish between the killing effects of
moxifloxacin, trovafloxacin and grepafloxacin when given at concentrations of
0.12mg/L. In an attempt to enhance undetected differences the therapeutic dose was
increased to 0.25mg/L, however this did not introduce significant variation in the
killing effects of the different agents. Since there was also no statistically significant
difference between cohorts of animals treated with antibiotic and the untreated
controls at either dose, it would appear that there was an error in the doses given.
Each cohort of mice in the dose-response experiment was administered the correct
concentration of quinolone, relative to the other cohorts, because the initial stock
solution was diluted 1 in 2 each time rather than fresh stocks made up for each
individual concentration. Therefore, even if errors were introduced in the actual
intra-abscess concentration, dosing group 4 (4 times MIC) had twice the dose of
group 3 (2 times MIC), which had twice the dose of group 2 (MIC dose), so any error
in the initial stock concentration might not be detected. However, in the quinolone
comparison studies where the same single concentration was used for all quinolones
given to all mice this kind of problem would show up more readily. In a future study
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it would be useful to evaluate the quinolone concentration in abscesses as well as
viable counts in order to establish that the appropriate intra-abscess concentration has
been achieved.
Interestingly, it was relatively difficult to recover quinolone-resistant mutants from
abscess material after therapy when this model was used to investigate the in vivo
development of resistance. Although the mutation frequencies for selection of
first-step in vivo mutants were higher than in vitro mutants (10compared to 10"7)
the number of recoverable mutants from treated abscesses was very low. As with the
majority of first-step in vitro mutants, DNA sequencing of the QRDRs of gr/A and
gyrA from first-step in vivo mutants did not reveal any mutations to account for the
increase in MIC from 0.05 to 0.13mg/L. No second-step mutants could be recovered
from first-step in vivo strain ED427. However, when second-step selection was
repeated with double the inoculum of strain EDI70 a single mutant strain was
detected with a gyrA serine 84 to leucine mutation. From these data, the progression
of resistance in vivo from sensitive strain to second-step mutant mirrors the in vitro
situation with progression following the right hand pathway shown in Figure 8.2.
However, since the numbers of mutants identified in these experiments were very
low, care must be taken in making such an assumption. Also, this would imply that
single gyrA mutants might be commonly found in the clinical situation, while most




While this in vivo study may reflect some aspects of the clinical progression of
resistance in S. aureus isolates exposed to quinolones, strain NCTC 8325/4 is
obviously not a clinical strain. The relatedness of this strain to clinically relevant
pathogens has not been investigated, therefore it is not clear how accurately this
model may reflect the step-wise development of resistance in clinical isolates. The
site of infection, tissue penetration, protein binding, and route of antibiotic
administration are some of the factors that influence the outcome of therapy and are
thus carefully investigated during the development of a new agent such as
moxifloxacin (Stass and Kubitza, 1999; Dalhoff, 1999; Sullivan et al. 1999; Siefert
etal. 1999a; Siefert et al. 1999b; Stass el al. 1998). These factors affect the in vivo
concentration of an antibiotic at the site of infection and will therefore also influence
the development of resistance, since sub-MIC concentrations are more likely to
promote the development of resistance in vivo (Doss et al. 1995). It would therefore
be interesting to investigate the step-wise development of resistance in other models
such as the mouse tuberculosis model (Miyazaki et al. 1999), the neutropoenic thigh
mode! (Dalhoff, 1999), the prosthetic implant model (Cagni et al. 1995) or the
endocarditis model (Entenza et al. 1999), in order to evaluate whether the results




This thesis has investigated the mechanisms of action, the step-wise development of
resistance and the primary molecular targets of moxifloxacin in S. aureus, both in
vitro and in vivo. Moxifloxacin was found to have bactericidal activity against both
sensitive and resistant clinical and laboratory-derived strains of S. aureus. Time-kill
kinetics indicated killing by more than one bactericidal mechanism. Step-wise
selection of quinolone-resistant mutants generated strains with mutations in the
QRDRs of both gyrA and grlA. However, the progression of resistance was different
from previously published work. The majority of first-step strains had an unknown
mutation rather than a change in grlA - a single strain had a grlA mutation.
Subsequent second-step strains all had gyrA mutations irrespective of whether the
first-step parent had a grlA mutation or not. Third-step mutants had high level
resistance with one gyrA, one grlA and one unknown mutation. Similar results were
found with both ciprofloxacin-selected mutants and in vivo moxifloxacin-selected
mutants. These results indicate that DNA gyrase is the primary molecular target in
S. aureus, and not topoisomerase IV as has been assumed from previous studies. It
must be conceded, however, that this conclusion may only be true for strain NCTC
8325/4 and resistant derivatives, as no other strains have been investigated. This
study therefore highlights the caution required in interpreting such results, as any
general conclusion about molecular targets based on this study may not be applicable
to all strains and all quinolones. A study was made of the in vivo development of
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resistance to moxifloxacin in strain NCTC 8325/4 in a murine subcutaneous abscess
model. Topoisomerase IV mutations were rarely selected in first-step mutants, and
gyrA mutations were selected without grlA mutations in second-step mutants. This
mutation pattern correlated with previous in vitro results pointing to DNA gyrase as
the primary mutational target in vivo. However, irrespective of whether DNA gyrase
or topoisomerase IV is the primary target in S. aureus, this study was undertaken
with a standard laboratory strain, and it therefore remains unclear how well these
results relate to the development of quinolone resistance in clinically significant
strains.
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Appendix I: Sensitivities of First-step Mutants to
Moxifloxacin
Isolate Selection at MIC Change in Resistance
Number (mg/L) (mg/L) (factor x MIC)
NCTC 8325/4* - 0.05 -
ED 170 0.125 0.125 2.5
ED171 0.125 0.150 oJ
ED 172 0.125 0.125 2.5
ED 173 0.125 0.125 2.5
ED 174 0.125 0.175 3.5
ED 175 0.125 0.125 2.5
ED 176 0.125 0.125 2.5
EDI 77 0.125 0.150 3
EDI 78 0.125 0.150 J
ED 179 0.125 0.125 2.5
EDI 80 0.125 0.175 3.5
ED181 0.125 0.125 2.5
ED182 0.125 0.125 2.5
EDI 83 0.125 0.125 2.5
ED 184 0.125 0.125 2.5
ED 185 0.125 0.125 2.5
ED 186 0.125 0.125 2.5
EDI 87 0.125 0.125 2.5
ED188 0.125 0.125 2.5
ED 189 0.125 0.150 3
ED 190 0.125 0.125 2.5
EDI 91 0.125 0.150 3
ED 192 0.125 0.125 2.5
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Isolate Selection at MIC Change in Resistance
Number (mg/L) (mg/L) (factor x MIC)
1-D193 0.125 0100 2
ED 194 0.125 0.125 2.5
ED 195 0.125 0.100 2
ED 196 0.125 0.125 2.5
ED197 0.125 0.100 2
EDI 98 0.125 0.125 2.5
EDI 99 0.125 0.100 2
ED200 0.125 0.100 2
ED201 0.125 0.050 1
ED202 0.150 0.150 oJ
ED203 0.150 0.100 2
ED204 0.150 0.100 2
ED205 0.150 0.100 2
ED206 0.150 0.150 3
ED207 0.150 0.100 2
ED208 0.150 0.075 1.5
ED209 0.150 0.125 2.5
ED210 0.150 0.050 1
ED211 0.150 0.050 1
ED212 0.150 0.050 1
ED213 0.175 0.150 o
ED214 0.175 0.100 2
ED215 0.175 0.075 1.5
ED216 0.175 0.125 2.5
ED217 0.175 0.050 1
ED219 0.175 0.125 2.5
ED220 0.175 0.250 5
ED221 0.200 0.100 2
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Isolate Selection at MIC Change in Resistance
Number (mg/L) (mg/L) (factor x MIC)
ED222 0.200 0.125 2.5
ED223 0.200 0.125 2.5
ED224 0.200 0.100 2
ED225 0.200 0.100 2
ED226 0.200 0.100 2
ED227 0.200 0.100 2
ED228 0.200 0.150 3
ED229 0.200 0.125 2.5
ED230 0.200 0.100 2
ED231 0.200 0.125 2.5
ED232 0.200 0.100 2
ED233 0.200 0.125 2.5
ED234 0.200 0.100 2
ED235 0.200 0.125 2.5
ED236 0.200 0.100 2
ED237 0.200 0.125 2.5
ED238 0.200 0.100 2
ED239 0.200 0.125 2.5
ED240 0.200 0.125 2.5
ED241 0.200 0.100 2
ED242 0.200 0.125 2.5
ED243 0.200 0.100 2
ED244 0.200 0.100 2
ED245 0.200 0.100 2
ED246 0.200 0.100 2
ED247 0.200 0.125 2.5
ED248 0.200 0.125 2.5
ED249 0.200 0.125 2.5
136
Appendix I: Sensitivities of First-step Mutants to Moxifloxacin
Isolate Selection at MIC Change in Resistance
Number (mg/L) (mg/L) (factor x MIC)
ED250 0.200 0.125 2.5
ED251 0.200 0.050 1
ED252 0.200 0.100 2
ED253 0.200 0.050 1
ED254 0.200 0.050 1
ED255 0.200 0.125 2.5
ED256 0.200 0.100 2
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Appendix II: Sensitivities of Second-step Mutants to
Moxifloxacin
Parent Isolate Selection at MIC Change in Resistance
Strain number (mg/L) (mg/L) (factor x MIC)
ED223 ED258 0.4 0.8 16
ED259 0.4 1.0 20
ED260 0.4 2.0 40
ED261 0.4 0.8 16
ED262 0.6 2.0 40
ED263 0.8 2.0 40
ED264 0.8 2.0 40
ED265 0.8 2.0 40
ED229 ED266 0.4 0.8 16
ED267 0.4 0.8 16
ED268 0.4 0.8 16
ED269 0.4 0.8 16
ED270 0.4 0.4 8
ED271 0.4 0.4 8
ED272 0.4 0.2 4
ED274 0.4 0.2 4
ED276 0.6 0.8 16
ED277 0.8 0.8 16
ED231 ED278 0.4 0.4 8
ED279 0.4 0.2 4
ED280 0.4 0.2 4
ED281 0.4 0.2 4
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Parent Isolate Selection at MIC Change in Resistance
Strain number (mg/L) (mg/L) (factor x MIC)
ED282 0.4 0.4 8
ED283 0.6 0.8 16
ED233 ED284 0.4 0.4 8
ED285 0.4 0.4 8
ED235 ED292 0.4 0.8 16
ED293 0.4 0.8 16
ED294 0.4 0.8 16
ED295 0.4 0.4 8
ED296 0.4 0.4 8
ED297 0.4 0.4 8
ED298 0.4 0.4 8
ED299 0.4 0.4 8
ED237 ED300 0.4 0.4 8
ED239 ED306 0.4 0.8 16
ED308 0.4 0.8 16
ED309 0.4 0.8 16
ED310 0.4 0.8 16
ED311 0.4 0.8 16
ED240 ED312 0.4 0.8 16
ED313 0.4 2.0
ED314 0.4 0.8 16
ED315 0.4 0.8 16
ED316 0.6 0.2 4
ED318 0.6 0.8 16
ED319 0.6 0.8 16
ED320 0.6 1.0 20
ED321 0.8 1.0 20
Total 6 12 22 3
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Appendix IV: Statistical Analyses of In Vivo Dose Response Data
Appendix IV: Statistical Analyses of In Vivo Dose
Response Data
Table I shows the raw data of triplicate plate counts of cfus recovered from abscess
material from animals given 0, 1, 2 or 4 times MIC of moxifloxacin. The means
used for statistical analyses are given in Table II. Statistical analyses were
performed by Mr Bill Adams, Medical Statistics, University of Edinburgh.
Table I: Raw data - Cfus recovered from staphylococcal abscesses
Cell counts in triplicate from dilutions of
Group to2 to4 to6
1 - - - 19 14 43 0 0 0
1 - - - 476 444 308 0 0 3
1 - - - 744 816 700 15 8 16
1 - - - 65 104 68 8 4 8
1
1






1 - - - 1008 796 832 6 18 12
1 - - - 39 36 38 2 1 6
1 - - - 356 360 353 4 6 0
1 - - - 776 744 - 79 159 84
2 1108 2148 1680 2 1 1 0 0 0
2 2212 1080 - 21 6 7 0 0 0
2 717 690 912 31 1 2 1 0 0
2 2496 - - 14 44 30 0 0 0
2 840 1136 1970 12 6 0 0 0 0
2 - - - 10 23 17 0 1 0
2 - - - 45 30 18 0 0 0
2 - - - 161 43 59 1 3 0
2 840 1348 268 ->J 3 3 0 0 1
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Cell counts in triplicate from dilutions of
Group to2 10 4 10 6
3 1500 711 878 20 33 25 0 0 1
3 - - - 53 52 46 1 0 0
->
J 325 216 344 0 0 0 0 0 0
-»
J 704 208 556 9 28 8 0 1 0
■J
J 524 452 304 7 8 7 0 1 0
3 - - - 71 8 7 0 1 0
3 1616 872 1764 23 30 36 0 1 0
-y
J 209 167 166 1 2 2 0 0 0
3 291 384 629 3 1 1 0 0 0
4 96 62 103 0 1 0 0 0 0
4 38 716 180 1 1 0 0 0 0
4 751 1352 680 4 6 5 0 0 0
4 - 716 434 104 94 32 31 24 17
4 374 157 188 2 4 4 0 0 0
4 526 531 632 11 5 5 0 0 0
4 1368 1044 1139 9 9 13 0 0 0
4 2800 - 1556 16 4 7 1 0 0
4 361 816 988 11 8 3 1 0 0
4 993 716 577 _ _ _ _ _ _
Tabie II: Cfu means used for statistical analyses
Group Dilution Cell count Dilution Cell Count
I 10 4 25 10"6 0
1 10"4 409 10-6 1
1 10"4 753 10"6 13
1 10"4 79 10"6 7
1 10'4 1088 10"6 71
1 10~4 - 10-6 146
1 10"4 879 10"6 12
1 10"4 38 10"6 3
1 10"4 356 10-6 3
I 10"4 760 10"6 107
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Group Dilution Cell count Dilution Cell Coi
2 l()"2 1645 io-4 1
2 10-2 1646 10"4 11
2 10"2 773 10-4 11
2 10"2 2496 10-4 29
2 10"2 1315 10"4 6
2 10"2 - 10"4 17
2 10"2 - 10-4 31
2 10"2 - 10"4 88
2 10"2 819 10"4 5
J 10"2 1030 10-4 26
3 10"2 - 10"4 50
~»
J 10"2 295 10"4 0
3 lO'2 489 10-4 15
3 10"2 427 10-4 7
3 icr2 - 10"4 62
3 10"2 1417 10"4 30
3 10"2 181 10-4 2
->
J icr2 435 10"4 2
4 10"2 87 10-4 0
4 10'2 311 10-4 1
4 10"2 928 10"4 5
4 10"2 575 10-4 77
4 10-2 240 10-4 3
4 10"2 563 10"4 7
4 10"2 1184 10-4 10
4 10"2 2178 10"4 9
4 10"2 742 10-4 7
4 10"2 762 10-4 _
When cell counts are estimated by dilution methods the cell counts are plotted
against the dilution factor and data fitted to a straight line through the origin. There is
a line for each individual mouse. Unfortunately in this data set the dilutions were too
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high or too low leaving only two points, 10 4 and either 10"2 or 10~6. Thus giving




or simply , - c
Ki
Estimate c, the gradient of the line from juitthe number of cell counts and kt the
dilution factor. The sample values of^ are r, the actual cell counts. When working
with cell counts the natural distribution to use is the Poisson where the variance of a
mean value is equal to the mean. Unfortunately this data has a variation much higher
than expected. We get a measure of the variation from the 3 replicates which were
made on each reading. Plotting the log values shown in Figure I we get a line with a
gradient of 1.50. This means that
var(fii)= fu\'"
There is also one other source of variation: the mice. Different mice had to be used
for different experiments. Thus (1) can be written as
— = c + 8mi (2)
where 8m, is the mouse variation.
147
Appendix IV: Statistical Analyses of In Vivo Dose Response Data












7 J 1 5 0
log mean cell count
Table III: Mean and sample variance of each group at dilution 104
Dosing Raw values Log values
Group Mean Variance Mean Variance
1 488 158000 5.58 2.049
2 23 710 2.64 1.161
-)
J 23 506 2.41 2.157
4 14 576 1.93 1.408
Looking at Table III it can be seen that for the raw data the variation is ten times
higher than expected; the variation is not expected to be the same for each group
since the variation is oc 3However, the variation between the individual mice
should be the same for all 4 groups.
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log —— — c + 8mi
k: (3)
It can be seen in Table III how the log transform has reduced the differences in
variation of the 4 groups. All readings need to be standardised for a dilution of 10"4.
A straight line is fitted for each mouse, where r, is the cell count and k, the dilution.
log ri = c + kj i- 1,2
For this problem the method of quasi likelihood and not the ordinary least squares
method is used. The method is given by equations (6) and (7).













From this the following is obtained
r \




(7)log a, = c + log kt
c must be solved in two stages. Into equation (6) put A; = T solving the right hand
side gives c. Then put c into equation (7); thus a new value for //, is determined. This
is put back into (6), giving a new value of c. The process is repeated until c remains
constant. Estimates of c together with the standard error are given in Table IV.
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Table TV: Estimated log values for dilution 10~4
Group 1 Group 2 Group 3 Group 4
estimate standard estimate standard estimate standard estimate standard
error error error error
3.497 0.398 2.720 0.153 2.470 0.163 -0.082 0.308
5.969 0.214 2.778 0.151 3.938 0.113 1.096 0.229
6.701 0.179 2.099 0.178 1.023 0.233 2.196 0.174
4.959 0.276 3.237 0.134 1.777 0.193 2.509 0.161
7.405 0.150 2.534 0.160 1.536 0.205 0.948 0.238
9.593 0.087 2.872 0.147 4.143 0.107 1.767 0.194
6.822 0.173 3.466 0.127 2.753 0.152 2.468 0.163
4.270 0.328 4.485 0.098 0.639 0.257 3.031 0.141
5.898 0.218 2.075 0.179 1.436 0.211 2.016 0.182
7.425 0.149 _ _ _ _ 2.032 0.181
From Table IV the mean and variances for each group are calculated. The standard
errors of each estimate obtained from equation (5) using the fitted line are also listed
in Table IV. They are all of the same magnitude and are lower than the variances for
each group i.e., the variance between mice. Thus the sample variance is used to
calculate the standard error. This gives upper and lower confidence limits of each
log mean. Anti-logs are taken to return data to the original scale. The results are
shown in Table V.
Table V: Estimated mean cell count at 10"4 dilution
Confidence Limits
Group Mean Upper 95% Lower 95%
1 520.05 1580.1 171.2
2 18.51 30.4 11.3
3 8.94 20.4 3.9
4 6.04 10 8 3.4
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Group 4 is significantly lower than group 2. Group 2 has high variance. The
variation of the data is unexpectedly high. It should be given by,
but is instead n) ~
If more than 2 data points were available for fitting the lines this value could have
been attributed to outliers.
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Appendix V: Statistical Analyses of Quinolone
Comparison at 2 times MIC
When analysing data for cell counts the natural distribution to use is the Poisson. If
this is confirmed when the data is tested, it bolsters confidence in the experimental
technique. Such a test can be made when 3 replicates are available for each mouse.
This is given by
xl =f}r,~U^ (!)
M l'i
where rt is the /'th replicate
ui is the mean of the 3 readings
These chi square values, with 2 degrees of freedom (d.f.) are given in Table I. There
are 2 outliers in this data, values in bold face, 187 and 31. When these are eliminated
the probability plot in Figure I is obtained; when the data is Poisson the points should
lie about the solid line which is indeed the case.
The next stage is to test for homogeneity in each group for the means in Table I.
Denote this mean as
m =
n
Then if the group is homogenous the standard error (s.e.) of the mean is that of a
Poisson
s.e.(m) =
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Table I: Data with mean and chi square values
Mean Chi square
Group Replicates x\
c 40 38 40 39.33 0.07
c 40 40 38 39.33 0.07
c 53 50 55 52.67 0.24
c 70 187 54 103.67 101.72
c 26 28 17 23.67 2.90
c 35 20 17 24.00 7.75
c 18 24 21 21.00 0.86
m 51 37 56 48.00 4.04
m 21 21 18 20.00 0.30
m 53 61 56 56.67 0.58
m 65 60 67 64.00 0.41
m 94 89 103 95.33 1.06
m 20 19 20 19.67 0.03
m 6 8 4 6.00 1.33
m 51 42 32 41.67 4.34
m 27 29 26 27.33 0.17
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Mean Chi square
Group Replicates "/ x2
t 18 31 12 20.33 9.28
t 14 14 14 14.00 0.00
t 29 28 19 25.33 2.39
t 23 33 37 31.00 3.35
1 9 12 6 9.00 2.00
t 164 171 156 163.67 0.69
t 125 117 118 120.00 0.32
t 5 8 6 6.33 0.74
t 5 9 9 7.67 1.39
t 47 72 66 61.67 5.52
g 25 25 30 26.67 0.63
g 108 97 111 105.33 1.03
g 62 87 69 72.67 4.58
g 28 30 34 30.67 0.61
g 65 71 62 66.00 0.64
g 59 53 53 55.00 0.44
g 96 100 111 102.33 1.18
g 15 16 19 16.67 0.52
g 51 47 55 51.00 0.63
The values given in Table II are all highly significant. This means there is a huge
natural variation between the mice since from Figure I it cannot be due to sloppy
counting. To test for difference in means, the mouse variation (given in Table III)
and not that of a Poisson must be used. Box plots were used to get an idea of the
distribution of the means in Table I, and these are given in Figures II and III. The
horizontal line in each box is the median; the bottom and top are 25% and 75%
quantiles. The ends are the maximum and minimum.
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Table III: Means and variances
Group Reps
Raw data Log values
Mean Variance Mean Variance
c 7 37.43 247 3.546 0.1795
m 9 42.07 759 3.492 0.6889
t 10 45.37 2957 3.210 1.3083
g 9 58.48 997 3.913 0.3919
In Figure II group t shows a highly skewed distribution. Transformation to logs in
Figure III removes this; the log transformation can pass as normalising the data and t
tests can be used to compare means. Unfortunately the variance (Table II) and the
ranges (Figure III) show groups m and / as much higher than c and g. For unequal
variances the equivalent of a t test is the Behrens Fisher test. The biggest difference
(c from g) as a rough test distributed as a t gives
3.913-3.546
t= ,
6x0.1797 + 8x0.3919 f\ 1^
x
V 14
= 1.32 attest with 14 d.f.
v7 + 9 j
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which is not significant. In conclusion, it can be seen that there are no significant
differences between groups. For the differences to be significant a sample size in
each group of about 60 animals, or a more uniform model is required.
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Appendix VI: Statistical Analyses of Quinolone
Comparison at 4 times MIC
These statistical analyses were performed with Genstat 5 (release 4.1) by Mr Bill
Adams (Medical Statistics, University of Edinburgh). The raw data are given in
Table I, and a detailed print out of the program processes follow.
Table I: Raw data of cfus from animals treated with 4 times MIC of
moxifloxacin
Group Triplicate cell counts from 10" dilution
c 13 16 18
c 33 51 46
c 52 51 49
c 50 52 57
c 29 38 26
c 27 21 32
m 54 53 51
m 23 12 17
m 19 11 14
m 844 77 26
m 24 15 27
m 110 84 62
m 41 28 11
in 18 25 20
m 78 54 80
m 51 80 76
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Group Triplicate cell counts from 10":, dilution
t 49 42 51
t 79 99 81
t 14 8 J
t 44 30 25
t 16 9 3
t 11 21 17
t 20 20 22
t 31 48 47
t 49 62 63
g 47 42 47
g 40 43 49
g 9 7 11
g 23 41 29
g 26 22 18
g 11 15 12
1. job'durll'
2. open 'data'; ch=2;file=input
3. units [nv=31]
4. factor[lev=4; lab=!t(c, m, t, g) grp; val=!(6(l),10(2),9(3),6(4))
5. read[ch=2] x[ 1... 3]
158
Appendix VI: Statistical Analyses ot'Quinolone Comparison at 4 times MIC
Table II: Ranges and means
Identifier Minimum Mean Maximum Values Missing
x[l] 9.00 37.90 110.00 31 0
x[2] 7.00 37.97 99.00 31 0
x[3] 3.00 35.16 81.00 31 0
6. calc vx=vmean(!p(x[l,2,3]))
7. tabulate [class=grp] vx;means=ttl; var=tt2
8. print ttl,tt2






9. scalar sm[l ...4]
10. equate ttl;!p(sm[l ...4])
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Table IV: Log values of means, standard error and variance
Group Mean (tttl) s.e. (ttt2) variance (ttt3)
c3.522 0.1900 0.2166
m 3.599 0.2116 0.4478
t 3.310 0.2718 0.6649





Table V: Analysis of variance
Source of Variation d.f. s.s. m.s. v.r. F pr.
grp 3 1089.9 363.3 0.71 0.557
Residual 27 13904.2 515.0
Total 30 14994.1
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MESSAGE: the following units have large residuals,
units 18 50.6 s.e. 21.2




c m t g
36.7 44.2 35.7 27.3
6 10 9 6
******Standard errors of difference ofmeans******
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Table VIII: Variance
Source of d.f. s.s. m.s. v.r. F pr.
Variation
grp 3 0.9514 0.3171 0.68 0.573






grp c in t g
3.52 3.60 3.31 3.14
rep. 6 10 9 6







(No comparisons in categories where s.e.d. marked with an x)
27. stop
Conclusion: there are no significant differences between groups.
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Abstract
Moxifloxacin was tested against clinical and laboratory strains of Staphylococcus aureus. It
had good activity against this organism, with MICs of 0.03-0.06 mg/l. Viable counts over a
range of moxifloxacin concentrations demonstrated a concentration-dependent bacteri¬
cidal effect, which was not biphasic as has been seen for a number of earlier quinolones.
The optimum bactericidal effect against three strains of S. aureus was found to be with
1 mg/l. Two clinical isolates with resistance to methicillin and ciprofloxacin had reduced
sensitivity to moxifloxacin. However, moxifloxacin was still able to exert a bactericidal
effect against these strains at levels two-fold higher than the MIC. When organisms were
tested in the presence of chloramphenicol (a protein synthesis inhibitor) or in phosphate-
buffered saline, moxifloxacin still demonstrated a bactericidal effect, albeit reduced. This
indicates that moxifloxacin has more than one mode of action against staphylococci.
Introduction
The 1990s have been viewed by some as the
'Armageddon of antimicrobial agents' as more
and more multi-drug-resistant pathogens
emerge.' 2 It has become increasingly important
to find more effective antimicrobials with which to
treat infections caused by such organisms. The
quinolone class of antimicrobials targets the inter-
Correspondence to: EJ Durham
Tel: +44 (0) 131 650 8270: email: e.j.durham«Sed.ac.uk
Moxifloxacin in practice © 1999 Bayer pic
action of DNA gyrase and topoisomerase IV with
DNA, thus inhibiting DNA replication. Although a
variety of quinolones has been in clinical use for
some time, the mechanisms of quinolone action
at the molecular level and how these agents
bring about bacterial cell death are still not well
understood. Early quinolones had activity pre¬
dominantly against Gram-negative pathogens
and their efficacy against Gram-positive organ¬
isms was poor. Multi-drug-resistant Gram-posi¬
tive organisms, such as Staphylococcus aureus,
are now recognised as potentially untreatable
with traditional antibiotics. In a response to this.
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new agents with enhancea activity against Gram-
positive bacteria are being developed.3
Many workers have performed studies to
investigate the killing kinetics of quinolones in
vitro. Smith was the first to demonstrate the now
widely accepted biphasic response pattern char¬
acteristic of early quinolones.4 He found that the
survival rate of bacteria decreased to a minimum
at the optimum bactericidal concentration (OBC)
and then began to increase again as the concen¬
tration of quinolone increased. This effect was
attributed to the inhibition of protein synthesis at
concentrations greater than the OBC, a process
thought to be required for quinolone action.
Further work5 showed that when protein syn¬
thesis was inhibited by the addition of rifampicin,
first-generation quinolones. such as nalidixic acid,
were rendered ineffective, but second-generation
fluorinated quinolones retained some bactericidal
activity. These observations suggested two
mechanisms of killing action - mechanism A.
which required protein synthesis, and mechanism
B. which did not. Since then, a third mechanism,
designated C, has also been identified.6-7
Mechanism C is active against non-dividing cells
in phosphate-buffered saline (PBS) but is lost if
protein synthesis is inhibited. When a quinolone
has more than one mechanism of action, further
studies have indicated that the mechanism caus¬
ing bacterial death may be species specific. For
example, ciprofloxacin can kill Escherichia coli by
mechanisms A and B,5 but can kill coagulase-
negative staphylococci only using mechanism
B.s-9 However, as these studies were performed
using standard quinolone-sensitive laboratory
strains of bacteria their relevance to clinical
pathogens remains unclear.
Moxifloxacin (BAY 12-8039) is a new
8-methoxyfluoroquinolone that has been shown
to have good activity against Gram-positive bac¬
teria. including a range of staphylococcal
species.13-12 The aim of this study was to investi¬
gate the mechanisms of action of moxifloxacin
against both standard laboratory strains and clini¬
cal isolates of S. aureus.
Methods
Three standard S. aureus strains (NCTC 6571.
NCTC 8325/4 and E3T) and four clinical isolates
were examined. Clinical isolates ED3 and ED5
were resistant to both ciprofloxacin and methi-
cillin, and clinical isolates ED7 and ED9 were sen¬
sitive to both ciprofloxacin and methicillin. All
clinical isolates were obtained from Edinburgh
Royal Infirmary Diagnostic Laboratories. MICs for
moxifloxacin and ciprofloxacin against S. aureus
were determined by a standard agar dilution
method (British Society for Antimicrobial
Chemotherapy guidelines13) on Isosensitest (1ST)
agar (Oxoid. Basingstoke, UK) using a multipoint
inoculator (Denley, Billingshurst. UK) and an
inoculum size of 106 CFU/'ml.
The OBC, defined as the lowest concentration
giving the maximum killing effect, was deter¬
mined for three strains (E3T. NCTC 8325/4 and
NCTC 6571) by inoculating nutrient broth (Oxoid)
containing a range of moxifloxacin concentrations
with log-phase bacteria and incubating for 3 h at
37°C. Viable counts were determined from 0.1 ml
samples subcultured on to 1ST agar and incub¬
ated overnight at 37°C.
Killing kinetics of log-phase cultures of clinical
isolates ED7 and ED9 (sensitive to ciprofloxacin
and methicillin) were determined by exposure of
S. aureus strains to the OBC for a total period of
210 min. During this period samples were
removed every 30 min and viable counts were
determined on 1ST agar plates.
Log-phase cultures of resistant isolates ED3
and ED5 were exposed to 0.5, 1,2,4 and
8 x the MIC of moxifloxacin to S. aureus (MIC
2 mg/l) in nutrient broth for a total of 210 min.
Viable counts were determined from samples
removed every 30 min as described above.
Log-phase cultures of NCTC 6571 and NCTC
8325/4 were exposed to the OBC in PBS or in
nutrient broth containing a bacteriostatic concen¬
tration of chloramphenicol, an inhibitor of bac¬
terial protein synthesis,14 for 210 min. Viable
counts were determined from samples taken
everv 30 min as described above.
J
Table 1. MICs or moxifloxacn one ciprofloxacin against standard ana clinical strains or Stacmcccc:
aureus.
Strain Type of strain*' MIC (mg/l)
Moxifloxacin Ciprofloxacin
NCTC 65' 1 Standard 0.03 < 0.06
NCTC 8325, - Stancara 0.06 0.50
EST Stanaara O.Co <0.06
ED3 ;c;p?. methOc Clinical 2.00 > 8.00
ED5 tcipT methH) Clinical 2.00 >8.00
ED7 Clinical 0.06 <0.06
ED9 Clinical 0.06 0.12
"Clinical isolate or standard laooratory strain.
°CipB = ciprofloxacin resistant: methB = methicillin resistant.
Results
Table 1 shows the MICs of moxifloxacin and
ciprofloxacin against the S. aureus strains used.
The compounds had similar activity against four
of the five methiciilin-sensitive strains. One of
these strains. NCTC 8325/4 was more suscepti¬
ble to moxifloxacin than to ciprofloxacin. The
MICs of moxifloxacin and ciprofloxacin were
increased substantially against the two resistant
S. aureus strains, althougn moxifloxacin was still
the more active compound.
Figure 1 shows the effect of a range of con¬
centrations of moxifloxacin against three of the
sensitive strains. The effect of moxifloxacin is
concentration dependent but not biphasic. From
these results the OBC would be defined as
1 mg/l.
Figure 2 shows the activity of moxifloxacin at
1 mg/l (OBC) over 210 min against the two sensi¬
tive clinical isolates. ED7 and ED9. A good bac¬
tericidal effect was seen, with survival decreas¬
ing to below 1 % by 150 min for both strains.
Figures 3 and 4 show the activity of a range of
concentrations of moxifloxacin against the two
resistant clinical isolates, ED3 and ED5. The
same overall pattern of killing activity was
observed for both isolates. Moxifloxacin was not
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Figure 1. Bactericidal activity of moxifloxacin
against Staphylococcus aureus strains NCTC 6571,
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Figure 2. Bactericidal activity of moxifloxacin at
1.0 mg/l against two clinical isolates of
Staphylococcus aureus in nutrient broth, both
sensitive to moxifloxacin (MIC 0.06 mg/l).
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Figure 3. Bactericidal activity of moxifloxacin
against ciprofloxacin-resistant Staphylococcus
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Figure 4. Bactericidal activity of moxifloxacin
against ciprofloxacin-resistant Staphylococcus
















0 30 60 90 120 150 180 210
Time (min)
Figure 5. Bactericidal activity of moxifloxacin at
1.0 mg/l against Staphylococcus aureus strain
NCTC 6571 in the presence and absence of
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Figure 6. Bactericidal activity of moxifloxacin at
1.0 mg/l against Staphylococcus aureus strain
NCTC 8325/4 in the presence and absence of
chloramphenicol (moxifloxacin MIC 0.06 mg/l).
strains) against these resistant strains. However,
activity was restored when the concentration of
moxifloxacin was increased, with survival
decreasing to less than 1 % after only 90 min for
both strains at twice the MIC to S. aureus
14 mg/l) or higher.
Figures 5 and 6 show the effect of moxi¬
floxacin against two of the sensitive strains,
NCTC 6571 and NCTC 8325/4. in the presence
and absence of chloramphenicol. Although the
efficacy of moxifloxacin was reduced in the pres¬
ence of chloramphenicol compared with the rate
</
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of kiii in nutrient broth atone, it retained some
bactericidal activity, killing ud to 90% of oacteria.
Similarly, the killing activity of moxifloxacin was
not completely removed when the organisms
were suspended in PBS.
Discussion
Moxifloxacin has been shown oy several groups
to have good anti-staphylococcal activity'0-"'2
and to be slightly more active than sparfloxacin"
and levofloxacin,10 fluoroquinolones with
improved activity against Gram-positive
pathogens. Moxifloxacin also compares
favourably with other drugs used to treat respira¬
tory tract infections, including cefuroxime,
amoxycillin, penicillin G and clarithromycin." In
the present study, moxifloxacin was shown to be
highly bactericidal against standard laboratory
and clinical isolates of S, aureus that are sensitive
to methicillin and ciprofloxacin. A concentration -
dependent effect was seen, but this was not
biphasic as has been demonstrated with a num¬
ber of earlier quinolones.-1 A bactericidal effect
was also seen against two methicillin- and
ciprofloxacin-resistant clinical isolates. The MIC of
moxifloxacin against these isolates was higher
than that against sensitive strains, but at concen¬
trations above the MIC a concentration-depen¬
dent bactericidal effect was seen. At four times
the MiC there was a rapid reduction in bacterial
number. Moxifloxacin has also been shown to
produce a concentration-dependent bactericidal
effect against pneumococci by Klugman and
Capper15 and against S. aureus and pneumo¬
cocci by Dalhoff ef al.11
When organisms were tested in the presence
of a protein inhibitor, chloramphenicol, a reduced
effect was seen. However, moxifloxacin was still
bactericidal, indicating that it has more than one
mechanism of action. Similarly, moxifloxacin was
still able to kill organisms that were not multiply¬
ing (suspended in PBS), lending further support
to the idea that this agent has more than one
mechanism of action.
Conclusions
These results of this study show that rrrcxifloxacin
is bactericidal against both clinical and laboratory
strains of S. aureus and that while activity is con¬
centration dependent it is not biphasic. as has
been observed for older quinolones. Clinicai
strains of S. aureus resistant to ciprofloxacin can
still be killed effectively at concentrations of moxi¬
floxacin in excess of the MIC. Moxifloxacin also
seems to have more than one mechanism of
bactericidal action. Based on the results of these
in vitro studies, moxifloxacin appears to be a
promising bactericidal agent against S. aureus.
This work was presented in part at the 37th
Interscience Conference ofAntimicrobial Agents
and Chemotherapy, Toronto. 1997: Abstract
F-139.
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Abstract
A series of mutants of a strain of Staphylococcus aureus was obtained by plating the bac¬
teria out on agar containing a range of concentrations of the fluoroquinolone moxifloxacin.
Mutants growing at concentrations above the original MIC were selected and re-plated in
three consecutive steps. The MICs of moxifloxacin, ciprofloxacin, sparfloxacin and
trovafloxacin were determined against five mutants from each stage. Although the MICs of
all compounds tested increased sequentially, moxifloxacin and trovafloxacin were the least
affected of the compounds. Genomic DNA was extracted from the 15 strains and the poly¬
merase chain reaction (PCR) was used to amplify the quinolone resistance-determining
region of gyrA and grIA. Four of the first-step mutants had no gyrA or grIA mutations, but
one strain had a grIA mutation that was not accompanied by an increase in the MIC. Three
different gyrA mutations were present in the second-step mutants, accompanied by muta¬
tions in grIA in only two of the strains. All five third-step mutants (those with the highest
MICs) had identical mutations - Ser-84 to Leu in gyrA and Glu-84 to Lys in grIA. These
results suggest that topoisomerase may not be the most important target in S. aureus.
Introduction
The quinolones are a class of antimicrobials that
inhibit DNA synthesis by targeting bacterial DNA
gyrase and topoisomerase IV. Although their
exact mechanisms of action have yet to be deter-
Correspondence to: EJ Durham
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Moxifloxacin in practice © 1999 Bayer pic
mined, recent evidence suggests that DNA
gyrase is the primary quinolone target in Gram-
negative organisms while topoisomerase IV is the
primary target in Gram-positives.1-3 However,
some studies indicate that this is not the full
story, as new quinolones may have different tar¬
gets from their older counterparts within a single
species.4
Resistance to quinolones arises through
changes within the genes that encode for DNA
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gyrase (gvrA and gyrBi or topoisomerase IV (grIA
and grIB in Staphylococcus aureus). Sequencing
of gyrA and grIA genes from resistant mutants
has identified 'hot spots' of mutations, which are
commonly referred to as the quinolone resis¬
tance-determining regions or QRDRs.5-9 In
Gram-negative organisms, topoisomerase IV
mutations contribute to quinolone resistance to a
lesser degree than gyrase mutations, and are
believed to play a secondary role. In Gram-posi¬
tive organisms the situation seems to be
reversed, and gyrase mutations do not seem to
produce high-level quinolone resistance in such
bacteria unless certain topoisomerase IV muta¬
tions are already present.3 -'5 '0 '1' However, in
many mutants with altered quinolone susceptibil¬
ity no relevant changes to the QRDRs of either
the gyrase or topoisomerase IV genes have been
detected.12"'" and resistance may be attributed
to an efflux system encoded by norAr5 Mutation
in the norA gene leads to enhanced efflux of
quinolones. which has been shown to cause
moderate, but clinically relevant, levels of resis¬
tance in S. aureus.''2''1 6
Resistance to quinolones in S. aureus is
unusual in that a number of methicillin-resistant
strains, although resistant to older compounds
(norfloxacin, enofloxacin. ofloxacin and cipro¬
floxacin), remain sensitive to some of the newer
fluoroquinolones. This has been explained in
recent studies showing that classic gyrase and
topoisomerase mutations associated with resis¬
tance affect the newer quinolones to a lesser
degree than the older compounds.9'17"19 Single-
step mutants resistant to older quinolones can be
obtained, but these are not usually resistant to
the newer compounds. Mutants with more than a
one-step change seem to be required for resis¬
tance in DNA gyrase.20 This suggests that new
quinolones may interact differently with their tar¬
gets or have different or additional targets com¬
pared with older quinolones.
Moxifloxacin is a new 8-methoxyquinolone
with enhanced activity against Gram-positive
organisms. It has been shown to be less influ¬
enced than older quinolones by known mutations
in gyrA. gyrB. grIA and grIB.2' The purpose of
this studv was to determine the intracellular tar¬
gets oi moxifioxacin in S. aureus by sequence
analysis of the QRDR of gvrA, the gene encoding
for DNA gyrase. and the analogous region of
grIA. encoding for topoisomerase IV.
Methods
First-, second- and third-step quinolone-resistant
mutants of S. aureus were selected from a stan¬
dard sensitive parent strain (NCTC 8325/4) on a
series of Mueller-Hinton agar plates (Oxoid,
Basingstoke, UK) containing concentrations of
moxifloxacin at or above the MIC (Figure 1). The
MICs of moxifloxacin. ciprofloxacin, trovafloxacin
and sparfloxacin (supplied by Bayer AG.
Wuppertal, Germany) for the parent strain and all
mutants were initially determined by the standard
agar dilution method described in the British
Society for Antimicrobial Chemotherapy sensitiv¬
ity testing guidelines.22 Subsequently, more pre¬
cise values for moxifloxacin were determined by
using a narrow range of concentrations around
the value determined as the MIC by standard
methods, in order to ascertain the optimum start¬
ing concentration for subsequent selection
plates.
First-step mutants of the sensitive parent
strain were selected from colonies growing on
plates containing 0.125 mg/l of moxifloxacin (2.5






















Sensitivities: 2.5 x MIC 16 x MIC > 85 x MIC
0.05 mg/l 0.125 mg/l 0.8 mg/l > 4.25 mg/l
Figure 1. Moxifioxacin-resistant mutants of
Staphylococcus aureus selected in vitro.
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from the first-step mutants by plating out these
mutants on a range of moxifioxacin concentra¬
tions and selecting those colonies growing at
>2.5 times the MIC. Third-step mutants were
derived from second-step mutants with MICs of
0.8 mg/l (16 x the MIC of NCTC 8325/4). Viable
counts of all parent strains were determined at
each mutation step by subculturing on to non¬
selective plates to determine mutation frequen¬
cies. These were calculated by dividing the
number of colonies obtained on selective plates
by the number of viable organisms per 100 ,ui
when the same stock culture was spread on to
non-selective plates.
Five mutants chosen from each mutation step
were characterised by DNA sequencing. A rapid
extraction method23 was used to extract genom¬
ic DNA from whole staphylococcal cells, and
10 ul of extract were used for each polymerase
chain reaction (PCR) to amplify the QRDR of gyrA
and the analogous region of grIA. Oligonucleotide
primers (Immunogen International Ltd. Sunder-
iand. UK), detailed in Table 1, were combined
with other PCR reagents as follows: 10 pmol of
each primer, 200 uM dNTPs, 2.5 mM MgCI2 and
2 units of Taq DNA polymerase (all from
Promega. Southampton. UK). Thermal cycling
was performed with an initial denaturing step of
94°C for 30 s. 55'C for 30 s and 72CC for
10 min. This was followed by 30 cycles of 1 min
at 90°C for denaturation. 2 min at 42=C for
annealing and 3 min at 72°C for polymerisation.
The final extension step took place for 5 min at
72°C.
Purified PCR products were subjected to
cycle sequencing using an ABI PRISM
dRhodamine terminator cycle sequencing ready
reaction kit according to the manufacturer's
instructions (Perkin-Elmer. Seer Green. UK).
Extension products were ourifiea by rapid ethane
orecipitaticn and sequences determined by auto¬
matic sequencing or. an AEi PRISM DMA
sequencer (Perkin-Elmen. Ail strains were
sequenced twice from different PCR products to
confirm the results.
Results
The sensitivities of all the mutant strains isolated
are shown in Table 2. Moxifloxacin ana
trovafloxacin were slightly more active than
sparfloxacin, which was mere active than
ciprofloxacin against all strains. MIC values for all
four compounds increased gradually from first-
step mutants to third-step mutants.
Table 3 shows the mutation frequencies of the
three different types of mutants and the concen¬
tration of moxifloxacin at which they were isol¬
ated. Overall, the frequencies ranged between
3.3 x 10"r and 1.7 x 10"'2, the highest values
being found for the first-step mutants, and
decreasing for subsequent generations of
mutants with higher levels of resistance.
Table 4 shows the changes in the QRDRs of
the 15 mutants. It can be seen that four first-step
mutants with moxifloxacin MICs of 0.125 mg/l
(2.5 x the MIC of the parent strain. NCTC
3325/4) had no gyrA or grIA mutations. Although
the MIC of the fifth strain (ED223) was also
0.125 mg/l and it had no gyrA mutations, there
was a Ser-80 to Phe change in grIA. All of the
second-step mutants had an MIC 16 times that
of the parent strain, although three different
mutations (Ser-84 to Ala or Leu, or Glu-88 to Lys)
were present in gyrA. Only two strains. ED258
and ED261, had a change of Ser-80 to Phe in
the grIA gene inherited from their parent strain.
Table 1. Primer sequences.
Primer Sequence Size of amplified fragment
gyrA 5' GAC TTC TAA GCG CTG TGA AC
gyrA 3' AAG TTA CCT TGG CCA TCA AC 374 bases
grIA 5' TGT TTT AGG TGA TCG CTT TGG
grIA 3' GGC AAT ACC ATT GGT TCG AG 434 bases
i
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Table 2. MICs (mg/ii of rour quinoiones against 15 mutants of Stapnvlococcus aureus.
Mutation step Strain Ciprofloxacin Sparfloxacin Trovafloxacin Moxifloxacin
Parent NCTC 8325/4 0.5 0.05 0.06 0.06
First step ED170 2 0.25 0.12 0.12
ED209 1 0.06 0.06 0.12
ED216 2 0.06 0.12 0.12
ED223 2 0.25 0.25 0.12
ED229 1 0.06 0.12 0.12
Second step ED258 8 1 1 1
ED261 8 1 1 1
ED268 2 -f 0.25 1
ED276 2 1 0.25 1
ED277 2 1 0.5 1
Third step ED357 32 16 4 8
ED360 32 16 A 8
ED375 32 16 4 8
ED377 32 16 4 8
ED385 32 16 4 8
Table 3. Mutation frequencies of 15 moxifloxacin-resistant mutants of Staphylococcus aureus
NCTC 8325/4.






First step NCTC 8325-'4 0.125 2.5 3.3 x 10""
0.150 3 8.6 x 10"e
0.175 3.5 6.5 x 10"s
0.200 4 3.5 x 10"
Second step ED223 0.4 8 5.9 x 10"'
ED229 0.4 8 2.0 x 10-1"
0.6 12 2.5 x 10 ''
0.8 16 2.5 x 10"11
Third step ED268 1.2 24 1.4 x 10 "1*'
3.6 72 1.7 x 10"1*
4.2 84 1.7 x 10 12
This did not alter the MIC of moxifloxacin. but the
ciprofloxacin MIC increased four-fold. The other
three second-step mutants had no changes in
grIA, only in gyrA. All third-step mutants had a
Glu-84 to Lys change in grIA accompanied by a
Ser-84 to Leu change in gyrA. and had MICs of
4.25-4.5 mg/l (85-90 x the MIC of the parent
strain).
Discussion
In the past, work by several groups has suggest¬
ed that quinolone antibacterials have preferential
targets within bacteria depending on whether the
organism is Gram-positive or Gram-negative.
Until recently.2' it had been suggested by
many workers that a prerequisite for low-level
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resistance was a mutation within either gyrA or
grlA;2 however, the results of this study show four
first-step mutants with a clear, albeit small,
increase in MIC which cannot be attributed to
such mutations. This implicates some other resis¬
tance mechanism, such as gyrB or efflux muta¬
tions, both of which have been shown to cause
small decreases in sensitivity.15-24
Three second-step mutants were found to
have gyrA mutations in the absence of grIA muta¬
tions, despite the fact that S. aureus is a Gram-
positive organism. This casts some doubt on the
theory that topoisomerase IV is the primary target
for quinolones in Gram-positive organisms. Other
workers have suggested that the selective muta¬
tion specificity may be related to quinolone struc¬
ture rather than organism classification4 or that
quinolones may differ in their sensitivity to the
particular enzyme.2C However, as the structure-
function relationships of quinolones is still oniy
poorly understood, it is difficult to be conclusive
with such arguments.
Although other workers2 " have ascribed a
key role in the development of high-level resis¬
tance to changes within codon 80 of grIA. the
Ser-80 to Phe change observed in one first-step
and two second-step mutants did not confer an
increase in resistance to moxifloxacin. even when
combined with a mutation in gyrA. In contrast,
however, the Giu-84 to Lys mutation observed in
all third-step mutants had a considerable effect
by increasing the MIC by more than five-fold,
from 0.8 to 4.5 mg/l. This result agrees with pre¬
vious evidence that mutations which have an
effect on the sensitivity to older quinolones may
not have such a marked effect on the sensitivity
to newer fluoroquinolones, such as moxifloxacin.
This may be because the newer agents have dif¬
ferent targets from the older agents.17"19 The rea¬
son why gyrA mutations were found before grIA
mutations in most of our strains - a result in con¬
trast to those of previous studies - might be a
consequence of strain specificity. This seems
unlikely, however, as previous studies using a
variety of strains produced similar results to each
other. A possible explanation lies in the method¬
ology used: most groups used much higher
selection concentrations than those used in this
study, and this may affect which mutation
appears first. If this is the case, it is difficult to
identify, at this stage, which might be more
important clinically.
Our results suggest that topoisomerase IV is
not necessarily the primary target of moxifloxacin
in S. aureus, and that drug-specific interactions
may be as important as the bacterial species
in determining the stepwise development of
resistance.
Conclusions
A series of S. aureus mutants with decreased
sensitivity to moxifloxacin was isolated by
sequential plating out and changes in the QRDRs
of gyrA and grIA were examined. The increase in
MIC found with these mutants was less with
moxifloxacin and trovafloxacin than with
ciprofloxacin and sparfloxacin. Only one of the
first-step mutants had any changes in either gvrA
or grIA to account for the increase in MICs. Three
of the second-step mutants, those with a moder¬
ate degree of resistance to moxifloxacin and
ciprofloxacin, had mutations only in gyrA. indicat¬
ing that gyrase may be more important than
topoisomerase in these strains. When changes
were seen in both gyrA and grIA. this was
accompanied by a greater increase in resistance,
especially to ciprofloxacin. These results indicate
that the newer quinolones, such as moxifloxacin.
may not show the same reduction of activity as
older quinolones against staphylococci.
This work was presented in part at the 6th
International Symposium on New Quinolones.
Denver. CO. USA. 1998.
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